{
  "generated_at": "2026-02-28T03:39:20.146834Z",
  "environment": {
    "openalex_api_key_set": false,
    "pubmed_api_key_set": false,
    "artifacts_root": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts",
    "source_cache_root": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/cache/sources",
    "tool_http_timeout_seconds": 20,
    "tool_http_max_retries": 2
  },
  "lineage": {
    "thread_id": "tool-validate-thread-20260228T033857Z",
    "run_id": "tool-validate-run-20260228T033857Z",
    "request_index": 1,
    "user_msg_index": 1
  },
  "summary": {
    "tool_calls": 39,
    "status_counts": {
      "success": 27,
      "skipped": 11,
      "error": 1
    },
    "strict_mode": true,
    "strict_science_tools_checked": 28,
    "strict_science_tools_failed": 1,
    "core_checked": 28,
    "core_failed": 1,
    "core_passed": false,
    "optional_checked": 0,
    "optional_failures": [],
    "strict_passed": false,
    "strict_failure_tools": [
      "openfda_faers_aggregate"
    ]
  },
  "results": [
    {
      "tool": "rxnorm_resolve",
      "payload": {
        "term": "rapamycin",
        "max_candidates": 5
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Resolved 1 RxNorm candidate(s) for 'rapamycin'.",
          "data": {
            "query": "rapamycin",
            "candidates": [
              {
                "rxcui": "35302",
                "name": "sirolimus",
                "tty": "IN"
              }
            ],
            "best": {
              "rxcui": "35302",
              "name": "sirolimus",
              "tty": "IN"
            },
            "ingredient_rxcui": "35302"
          },
          "ids": [
            "35302"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "rxnorm_resolve.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/rxnorm_resolve/manual-001/raw/rxnorm_resolve.json",
              "sha256": "8d64b47c09b1677554176ed7b8eae2dd4877dbd5b476c7568b8f565e83d1194d",
              "size_bytes": 60
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "rxnorm",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:38:59.004151Z",
            "data_schema_version": "v1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-001"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 1471.43,
      "endpoint": "https://rxnav.nlm.nih.gov/REST/rxcui.json",
      "enabled": true
    },
    {
      "tool": "rxnorm_get_related_terms",
      "payload": {
        "rxcui": "35302"
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Fetched 74 related RxNorm concept(s) for 35302.",
          "data": {
            "rxcui": "35302",
            "related": [
              {
                "rxcui": "258355",
                "name": "Rapamune",
                "tty": "BN"
              },
              {
                "rxcui": "2586864",
                "name": "Fyarro",
                "tty": "BN"
              },
              {
                "rxcui": "2596865",
                "name": "Hyftor",
                "tty": "BN"
              },
              {
                "rxcui": "2717268",
                "name": "Felycin",
                "tty": "BN"
              },
              {
                "rxcui": "10312",
                "name": "Delayed Release Oral Tablet",
                "tty": "DF"
              },
              {
                "rxcui": "1649574",
                "name": "Injection",
                "tty": "DF"
              },
              {
                "rxcui": "316968",
                "name": "Oral Solution",
                "tty": "DF"
              },
              {
                "rxcui": "317541",
                "name": "Oral Tablet",
                "tty": "DF"
              },
              {
                "rxcui": "346286",
                "name": "Topical Gel",
                "tty": "DF"
              },
              {
                "rxcui": "1151122",
                "name": "Topical Product",
                "tty": "DFG"
              },
              {
                "rxcui": "1151126",
                "name": "Injectable Product",
                "tty": "DFG"
              },
              {
                "rxcui": "1151131",
                "name": "Oral Product",
                "tty": "DFG"
              },
              {
                "rxcui": "1151133",
                "name": "Pill",
                "tty": "DFG"
              },
              {
                "rxcui": "1151137",
                "name": "Oral Liquid Product",
                "tty": "DFG"
              },
              {
                "rxcui": "35302",
                "name": "sirolimus",
                "tty": "IN"
              },
              {
                "rxcui": "2712352",
                "name": "sirolimus protein-bound",
                "tty": "PIN"
              },
              {
                "rxcui": "2586868",
                "name": "sirolimus 100 MG Injection [Fyarro]",
                "tty": "SBD"
              },
              {
                "rxcui": "2596869",
                "name": "sirolimus 0.002 MG/MG Topical Gel [Hyftor]",
                "tty": "SBD"
              },
              {
                "rxcui": "2717273",
                "name": "sirolimus 2.4 MG Delayed Release Oral Tablet [Felycin]",
                "tty": "SBD"
              },
              {
                "rxcui": "2717277",
                "name": "sirolimus 1.2 MG Delayed Release Oral Tablet [Felycin]",
                "tty": "SBD"
              },
              {
                "rxcui": "2717281",
                "name": "sirolimus 0.4 MG Delayed Release Oral Tablet [Felycin]",
                "tty": "SBD"
              },
              {
                "rxcui": "351901",
                "name": "sirolimus 1 MG/ML Oral Solution [Rapamune]",
                "tty": "SBD"
              },
              {
                "rxcui": "351989",
                "name": "sirolimus 1 MG Oral Tablet [Rapamune]",
                "tty": "SBD"
              },
              {
                "rxcui": "404432",
                "name": "sirolimus 2 MG Oral Tablet [Rapamune]",
                "tty": "SBD"
              },
              {
                "rxcui": "905160",
                "name": "sirolimus 0.5 MG Oral Tablet [Rapamune]",
                "tty": "SBD"
              },
              {
                "rxcui": "2586865",
                "name": "sirolimus 100 MG [Fyarro]",
                "tty": "SBDC"
              },
              {
                "rxcui": "2596866",
                "name": "sirolimus 0.002 MG/MG [Hyftor]",
                "tty": "SBDC"
              },
              {
                "rxcui": "2717269",
                "name": "sirolimus 2.4 MG [Felycin]",
                "tty": "SBDC"
              },
              {
                "rxcui": "2717276",
                "name": "sirolimus 1.2 MG [Felycin]",
                "tty": "SBDC"
              },
              {
                "rxcui": "2717280",
                "name": "sirolimus 0.4 MG [Felycin]",
                "tty": "SBDC"
              },
              {
                "rxcui": "575659",
                "name": "sirolimus 1 MG/ML [Rapamune]",
                "tty": "SBDC"
              },
              {
                "rxcui": "575733",
                "name": "sirolimus 1 MG [Rapamune]",
                "tty": "SBDC"
              },
              {
                "rxcui": "576390",
                "name": "sirolimus 2 MG [Rapamune]",
                "tty": "SBDC"
              },
              {
                "rxcui": "905159",
                "name": "sirolimus 0.5 MG [Rapamune]",
                "tty": "SBDC"
              },
              {
                "rxcui": "2586867",
                "name": "sirolimus Injection [Fyarro]",
                "tty": "SBDF"
              },
              {
                "rxcui": "2596868",
                "name": "sirolimus Topical Gel [Hyftor]",
                "tty": "SBDF"
              },
              {
                "rxcui": "2717272",
                "name": "sirolimus Delayed Release Oral Tablet [Felycin]",
                "tty": "SBDF"
              },
              {
                "rxcui": "364904",
                "name": "sirolimus Oral Solution [Rapamune]",
                "tty": "SBDF"
              },
              {
                "rxcui": "368672",
                "name": "sirolimus Oral Tablet [Rapamune]",
                "tty": "SBDF"
              },
              {
                "rxcui": "1177701",
                "name": "Rapamune Oral Liquid Product",
                "tty": "SBDG"
              },
              {
                "rxcui": "1177702",
                "name": "Rapamune Oral Product",
                "tty": "SBDG"
              },
              {
                "rxcui": "1177703",
                "name": "Rapamune Pill",
                "tty": "SBDG"
              },
              {
                "rxcui": "2586866",
                "name": "Fyarro Injectable Product",
                "tty": "SBDG"
              },
              {
                "rxcui": "2596867",
                "name": "Hyftor Topical Product",
                "tty": "SBDG"
              },
              {
                "rxcui": "2717270",
                "name": "Felycin Oral Product",
                "tty": "SBDG"
              },
              {
                "rxcui": "2717271",
                "name": "Felycin Pill",
                "tty": "SBDG"
              },
              {
                "rxcui": "2586863",
                "name": "sirolimus 100 MG Injection",
                "tty": "SCD"
              },
              {
                "rxcui": "2596864",
                "name": "sirolimus 0.002 MG/MG Topical Gel",
                "tty": "SCD"
              },
              {
                "rxcui": "2717267",
                "name": "sirolimus 2.4 MG Delayed Release Oral Tablet",
                "tty": "SCD"
              },
              {
                "rxcui": "2717275",
                "name": "sirolimus 1.2 MG Delayed Release Oral Tablet",
                "tty": "SCD"
              },
              {
                "rxcui": "2717279",
                "name": "sirolimus 0.4 MG Delayed Release Oral Tablet",
                "tty": "SCD"
              },
              {
                "rxcui": "314230",
                "name": "sirolimus 1 MG/ML Oral Solution",
                "tty": "SCD"
              },
              {
                "rxcui": "349208",
                "name": "sirolimus 1 MG Oral Tablet",
                "tty": "SCD"
              },
              {
                "rxcui": "360110",
                "name": "sirolimus 2 MG Oral Tablet",
                "tty": "SCD"
              },
              {
                "rxcui": "905158",
                "name": "sirolimus 0.5 MG Oral Tablet",
                "tty": "SCD"
              },
              {
                "rxcui": "2586860",
                "name": "sirolimus 100 MG",
                "tty": "SCDC"
              },
              {
                "rxcui": "2596861",
                "name": "sirolimus 0.002 MG/MG",
                "tty": "SCDC"
              },
              {
                "rxcui": "2717265",
                "name": "sirolimus 2.4 MG",
                "tty": "SCDC"
              },
              {
                "rxcui": "2717274",
                "name": "sirolimus 1.2 MG",
                "tty": "SCDC"
              },
              {
                "rxcui": "2717278",
                "name": "sirolimus 0.4 MG",
                "tty": "SCDC"
              },
              {
                "rxcui": "333296",
                "name": "sirolimus 1 MG/ML",
                "tty": "SCDC"
              },
              {
                "rxcui": "350512",
                "name": "sirolimus 1 MG",
                "tty": "SCDC"
              },
              {
                "rxcui": "360318",
                "name": "sirolimus 2 MG",
                "tty": "SCDC"
              },
              {
                "rxcui": "905157",
                "name": "sirolimus 0.5 MG",
                "tty": "SCDC"
              },
              {
                "rxcui": "2586862",
                "name": "sirolimus Injection",
                "tty": "SCDF"
              },
              {
                "rxcui": "2596863",
                "name": "sirolimus Topical Gel",
                "tty": "SCDF"
              },
              {
                "rxcui": "2717266",
                "name": "sirolimus Delayed Release Oral Tablet",
                "tty": "SCDF"
              },
              {
                "rxcui": "375278",
                "name": "sirolimus Oral Solution",
                "tty": "SCDF"
              },
              {
                "rxcui": "378277",
                "name": "sirolimus Oral Tablet",
                "tty": "SCDF"
              },
              {
                "rxcui": "1158757",
                "name": "sirolimus Oral Liquid Product",
                "tty": "SCDG"
              },
              {
                "rxcui": "1158758",
                "name": "sirolimus Oral Product",
                "tty": "SCDG"
              },
              {
                "rxcui": "1158759",
                "name": "sirolimus Pill",
                "tty": "SCDG"
              },
              {
                "rxcui": "2586861",
                "name": "sirolimus Injectable Product",
                "tty": "SCDG"
              },
              {
                "rxcui": "2596862",
                "name": "sirolimus Topical Product",
                "tty": "SCDG"
              }
            ]
          },
          "ids": [
            "258355",
            "2586864",
            "2596865",
            "2717268",
            "10312",
            "1649574",
            "316968",
            "317541",
            "346286",
            "1151122",
            "1151126",
            "1151131",
            "1151133",
            "1151137",
            "35302",
            "2712352",
            "2586868",
            "2596869",
            "2717273",
            "2717277",
            "2717281",
            "351901",
            "351989",
            "404432",
            "905160",
            "2586865",
            "2596866",
            "2717269",
            "2717276",
            "2717280",
            "575659",
            "575733",
            "576390",
            "905159",
            "2586867",
            "2596868",
            "2717272",
            "364904",
            "368672",
            "1177701",
            "1177702",
            "1177703",
            "2586866",
            "2596867",
            "2717270",
            "2717271",
            "2586863",
            "2596864",
            "2717267",
            "2717275",
            "2717279",
            "314230",
            "349208",
            "360110",
            "905158",
            "2586860",
            "2596861",
            "2717265",
            "2717274",
            "2717278",
            "333296",
            "350512",
            "360318",
            "905157",
            "2586862",
            "2596863",
            "2717266",
            "375278",
            "378277",
            "1158757",
            "1158758",
            "1158759",
            "2586861",
            "2596862"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "rxnorm_allrelated_35302.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/rxnorm_get_related_terms/manual-002/raw/rxnorm_allrelated_35302.json",
              "sha256": "a4ba9a47415762c1ba5e01c0fcced7e94e39c287715e28b2fd4de317572c4396",
              "size_bytes": 19795
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "rxnorm",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:00.742637Z",
            "data_schema_version": "v1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-002"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 1737.4,
      "endpoint": "https://rxnav.nlm.nih.gov/REST/rxcui/{rxcui}/allrelated.json",
      "enabled": true
    },
    {
      "tool": "pubchem_resolve",
      "payload": {
        "name": "nicotinamide mononucleotide"
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Resolved PubChem compound for 'nicotinamide mononucleotide'.",
          "data": {
            "query": "nicotinamide mononucleotide",
            "cid": "14180",
            "preferred_name": "Nicotinamide Mononucleotide",
            "inchikey": "DAYLJWODMCOQEW-TURQNECASA-N",
            "canonical_smiles": null,
            "synonyms": [
              {
                "text": "1094-61-7",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "nicotinamide mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Nicotinamide ribotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "2KG6QX4W0V",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "DTXSID50911152",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Alpha9",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-carbamoyl-1-((2R,3R,4S,5R)-5-((hydrogen phosphonatooxy)methyl)-3,4-dihydroxyoxolan-2-yl)-1$l^(5)-pyridin-1-ylium",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "ELITEHEALTH",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "REUS NR",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "RefChem:854107",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Mononucleotide, Nicotinamide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "CHEBI:50383",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "DTXCID001511294",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "214-136-5",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-carboxy-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-((phosphonooxy)methyl)oxolan-2-yl)-1lambda5-pyridin-1-ylium",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta-Nicotinamide mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta-NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "NMN zwitterion",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "nicotinamide nucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "nicotinamide ribonucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta-nicotinamide D-ribonucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "nicotinamide D-ribonucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "BETANMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta-Nicotinamide ribonucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "MFCD00038748",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-(Aminocarbonyl)-1-(5-O-phosphonato-beta-D-ribofuranosyl)pyridinium",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "B-NICOTINAMIDE MONONUCLEOTIDE",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Nicotinamide ribonucleoside 5'-phosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta-nicotinamide ribose monophosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "b-D-NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "C11H15N2O8P",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "BETA-D-NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "UNII-2KG6QX4W0V",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "reinvigorator",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Fosribnicotinamide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "EINECS 214-136-5",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "ss-NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Nicotine Impurity 9",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Nicotinamidmononucleotid",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "fosribnicotinamide [INN]",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "-NM;NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "bmse000260",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "-Nicotinamide mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "?-Nicotinamidemononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Nicotinamide Mononucleotide?",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "NMN [MI]",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "|A-Nicotinamidemononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "?-Nicotinamide Mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "ss-Nicotinamide mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "fA-Nicotinamide Mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "SCHEMBL105618",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "|_-Nicotinamide Mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "CHEMBL610238",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "orb1302620",
                "source": "pubchem",
                "weight": 0.7
              }
            ]
          },
          "ids": [
            "14180",
            "DAYLJWODMCOQEW-TURQNECASA-N"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "pubchem_cids_nicotinamide_mononucleotide.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/pubchem_resolve/manual-003/raw/pubchem_cids_nicotinamide_mononucleotide.json",
              "sha256": "281a74573b3c7e085121f014cb67a406863bb644cf24d02f46f9973220bd08d9",
              "size_bytes": 60
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "pubchem",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:02.515963Z",
            "data_schema_version": "v1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-003"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 1772.85,
      "endpoint": "https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/{name}/cids/JSON",
      "enabled": true
    },
    {
      "tool": "pubchem_get_compound",
      "payload": {
        "cid": "14180"
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Fetched PubChem compound 14180.",
          "data": {
            "cid": "14180",
            "preferred_name": "Nicotinamide Mononucleotide",
            "inchikey": "DAYLJWODMCOQEW-TURQNECASA-N",
            "canonical_smiles": null,
            "synonyms": [
              {
                "text": "1094-61-7",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "nicotinamide mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Nicotinamide ribotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "2KG6QX4W0V",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "DTXSID50911152",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Alpha9",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-carbamoyl-1-((2R,3R,4S,5R)-5-((hydrogen phosphonatooxy)methyl)-3,4-dihydroxyoxolan-2-yl)-1$l^(5)-pyridin-1-ylium",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "ELITEHEALTH",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "REUS NR",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "RefChem:854107",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Mononucleotide, Nicotinamide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "CHEBI:50383",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "DTXCID001511294",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "214-136-5",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-carboxy-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-((phosphonooxy)methyl)oxolan-2-yl)-1lambda5-pyridin-1-ylium",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta-Nicotinamide mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta-NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "NMN zwitterion",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "nicotinamide nucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "nicotinamide ribonucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta-nicotinamide D-ribonucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "nicotinamide D-ribonucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "BETANMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta-Nicotinamide ribonucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "MFCD00038748",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-(Aminocarbonyl)-1-(5-O-phosphonato-beta-D-ribofuranosyl)pyridinium",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "B-NICOTINAMIDE MONONUCLEOTIDE",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Nicotinamide ribonucleoside 5'-phosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta-nicotinamide ribose monophosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "b-D-NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "C11H15N2O8P",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "BETA-D-NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "UNII-2KG6QX4W0V",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "reinvigorator",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Fosribnicotinamide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "EINECS 214-136-5",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "ss-NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Nicotine Impurity 9",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Nicotinamidmononucleotid",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "fosribnicotinamide [INN]",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "-NM;NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "bmse000260",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "-Nicotinamide mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "?-Nicotinamidemononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Nicotinamide Mononucleotide?",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "NMN [MI]",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "|A-Nicotinamidemononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "?-Nicotinamide Mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "ss-Nicotinamide mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "fA-Nicotinamide Mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "SCHEMBL105618",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "|_-Nicotinamide Mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "CHEMBL610238",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "orb1302620",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "SCHEMBL19064261",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta -Nicotinamide mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "CHEBI:16171",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "b-Nicotinamide ribose monophosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "GLXC-21427",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "EX-A3534",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "HY-F0004",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "BDBM50366763",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "MSK157075",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "|A-Nicotinamide Mononucleotide (NMN)",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-(Aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)pyridinium inner salt",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "AKOS015896881",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "CCG-267847",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "CS-4996",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "EBC-616152",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "NN45555",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-carbamoyl-1-beta-D-ribofuranosylpyridinium hydroxide 5'-(dihydrogen phosphate) inner salt",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "MSK157075-1000W",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1lambda5-pyridin-1-ylium",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "AC-35057",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "AS-59655",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "SY129470",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "N1123",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "C00455",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "H11919",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "F455506",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Q21547155",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta-Nicotinamide mononucleotide Solution in Water, 1000ug/mL",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta-Nicotinamide Mononucleotide(Discontinued,See C4X-20199)",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-Carbamoyl-1-[5-O-(hydroxyphosphinato)-beta-D-ribofuranosyl]pyridin-1-ium",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-carbamoyl-1-[5-O-(hydroxyphosphinato)-beta-D-ribofuranosyl]pyridinium",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-(AMINOCARBONYL)-1-(5-O-PHOSPHONO-.BETA.-D-RIBOFURANOSYL)PYRIDINIUM INNER SALT",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)pyridinium, inner salt",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "((2R,3S,4R,5R)-3,4-dihydroxy-5-(3-(hydroxy(imino)methyl)pyridin-1-ium-1-yl)tetrahydrofuran-2-yl)methyl hydrogen phosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "((2R,3S,4R,5R)-5-(3-carbamoylpyridinium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methylhydrogenphosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1??-pyridin-1-ylium",
                "source": "pubchem",
                "weight": 0.7
              }
            ]
          },
          "ids": [
            "14180",
            "DAYLJWODMCOQEW-TURQNECASA-N"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "pubchem",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:03.538131Z",
            "data_schema_version": "v1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-004"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 1023.08,
      "endpoint": "https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/{cid}/property/JSON",
      "enabled": true
    },
    {
      "tool": "ols_search_terms",
      "payload": {
        "q": "hyperbaric oxygen therapy",
        "ontologies": [
          "efo",
          "mondo",
          "hp"
        ],
        "rows": 5
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Found 5 ontology term candidate(s) for 'hyperbaric oxygen therapy'.",
          "data": {
            "query": "hyperbaric oxygen therapy",
            "page": 1,
            "hits": [
              {
                "obo_id": "EFO:0009796",
                "label": "response to supplemental oxygen",
                "iri": "http://www.ebi.ac.uk/efo/EFO_0009796",
                "ontology": "efo",
                "synonyms": [],
                "xrefs": []
              },
              {
                "obo_id": "EFO:0004887",
                "label": "maximal oxygen uptake measurement",
                "iri": "http://www.ebi.ac.uk/efo/EFO_0004887",
                "ontology": "efo",
                "synonyms": [],
                "xrefs": []
              },
              {
                "obo_id": "MONDO:0006450",
                "label": "therapy-related myeloid neoplasm",
                "iri": "http://purl.obolibrary.org/obo/MONDO_0006450",
                "ontology": "mondo",
                "synonyms": [],
                "xrefs": []
              },
              {
                "obo_id": "EFO:1000575",
                "label": "Therapy-Related Myeloid Neoplasm",
                "iri": "http://www.ebi.ac.uk/efo/EFO_1000575",
                "ontology": "efo",
                "synonyms": [],
                "xrefs": []
              },
              {
                "obo_id": "HP:0500259",
                "label": "Abnormal oxygen level in cord blood",
                "iri": "http://purl.obolibrary.org/obo/HP_0500259",
                "ontology": "hp",
                "synonyms": [],
                "xrefs": []
              }
            ],
            "best": {
              "obo_id": "EFO:0009796",
              "label": "response to supplemental oxygen",
              "iri": "http://www.ebi.ac.uk/efo/EFO_0009796",
              "ontology": "efo",
              "synonyms": [],
              "xrefs": []
            }
          },
          "ids": [
            "EFO:0009796",
            "EFO:0004887",
            "MONDO:0006450",
            "EFO:1000575",
            "HP:0500259"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": "2",
            "has_more": true
          },
          "source_meta": {
            "source": "ols",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:03.922859Z",
            "data_schema_version": "v1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-005"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 390.74,
      "endpoint": "https://www.ebi.ac.uk/ols4/api/search",
      "enabled": true
    },
    {
      "tool": "ols_get_term",
      "payload": {
        "iri": "http://www.ebi.ac.uk/efo/EFO_0009796",
        "ontology": "efo"
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Fetched ontology term.",
          "data": {
            "term": {
              "obo_id": "EFO:0009796",
              "label": "response to supplemental oxygen",
              "iri": "http://www.ebi.ac.uk/efo/EFO_0009796",
              "ontology": "efo",
              "synonyms": [
                "response to oxygen therapy"
              ],
              "xrefs": []
            },
            "tried_paths": [
              "ontology_terms_by_iri"
            ]
          },
          "ids": [
            "EFO:0009796"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "ols",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:04.122434Z",
            "data_schema_version": "v1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-006"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 191.42,
      "endpoint": "https://www.ebi.ac.uk/ols4/api/terms?iri={iri}",
      "enabled": true
    },
    {
      "tool": "concept_merge_candidates",
      "payload": {
        "user_text": "rapamycin",
        "rxnorm": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Resolved 1 RxNorm candidate(s) for 'rapamycin'.",
          "data": {
            "query": "rapamycin",
            "candidates": [
              {
                "rxcui": "35302",
                "name": "sirolimus",
                "tty": "IN"
              }
            ],
            "best": {
              "rxcui": "35302",
              "name": "sirolimus",
              "tty": "IN"
            },
            "ingredient_rxcui": "35302"
          },
          "ids": [
            "35302"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "rxnorm_resolve.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/rxnorm_resolve/manual-001/raw/rxnorm_resolve.json",
              "sha256": "8d64b47c09b1677554176ed7b8eae2dd4877dbd5b476c7568b8f565e83d1194d",
              "size_bytes": 60
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "rxnorm",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:38:59.004151Z",
            "data_schema_version": "v1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-001"
            }
          }
        },
        "pubchem": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Resolved PubChem compound for 'nicotinamide mononucleotide'.",
          "data": {
            "query": "nicotinamide mononucleotide",
            "cid": "14180",
            "preferred_name": "Nicotinamide Mononucleotide",
            "inchikey": "DAYLJWODMCOQEW-TURQNECASA-N",
            "canonical_smiles": null,
            "synonyms": [
              {
                "text": "1094-61-7",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "nicotinamide mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Nicotinamide ribotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "2KG6QX4W0V",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "DTXSID50911152",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Alpha9",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-carbamoyl-1-((2R,3R,4S,5R)-5-((hydrogen phosphonatooxy)methyl)-3,4-dihydroxyoxolan-2-yl)-1$l^(5)-pyridin-1-ylium",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "ELITEHEALTH",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "REUS NR",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "RefChem:854107",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Mononucleotide, Nicotinamide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "CHEBI:50383",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "DTXCID001511294",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "214-136-5",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-carboxy-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-((phosphonooxy)methyl)oxolan-2-yl)-1lambda5-pyridin-1-ylium",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta-Nicotinamide mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta-NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "NMN zwitterion",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "nicotinamide nucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "nicotinamide ribonucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta-nicotinamide D-ribonucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "nicotinamide D-ribonucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "BETANMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta-Nicotinamide ribonucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "MFCD00038748",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "3-(Aminocarbonyl)-1-(5-O-phosphonato-beta-D-ribofuranosyl)pyridinium",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "B-NICOTINAMIDE MONONUCLEOTIDE",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Nicotinamide ribonucleoside 5'-phosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "beta-nicotinamide ribose monophosphate",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "b-D-NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "C11H15N2O8P",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "BETA-D-NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "UNII-2KG6QX4W0V",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "reinvigorator",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Fosribnicotinamide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "EINECS 214-136-5",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "ss-NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Nicotine Impurity 9",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Nicotinamidmononucleotid",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "fosribnicotinamide [INN]",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "-NM;NMN",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "bmse000260",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "-Nicotinamide mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "?-Nicotinamidemononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "Nicotinamide Mononucleotide?",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "NMN [MI]",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "|A-Nicotinamidemononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "?-Nicotinamide Mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "ss-Nicotinamide mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "fA-Nicotinamide Mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "SCHEMBL105618",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "|_-Nicotinamide Mononucleotide",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "CHEMBL610238",
                "source": "pubchem",
                "weight": 0.7
              },
              {
                "text": "orb1302620",
                "source": "pubchem",
                "weight": 0.7
              }
            ]
          },
          "ids": [
            "14180",
            "DAYLJWODMCOQEW-TURQNECASA-N"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "pubchem_cids_nicotinamide_mononucleotide.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/pubchem_resolve/manual-003/raw/pubchem_cids_nicotinamide_mononucleotide.json",
              "sha256": "281a74573b3c7e085121f014cb67a406863bb644cf24d02f46f9973220bd08d9",
              "size_bytes": 60
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "pubchem",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:02.515963Z",
            "data_schema_version": "v1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-003"
            }
          }
        },
        "ols": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Found 5 ontology term candidate(s) for 'hyperbaric oxygen therapy'.",
          "data": {
            "query": "hyperbaric oxygen therapy",
            "page": 1,
            "hits": [
              {
                "obo_id": "EFO:0009796",
                "label": "response to supplemental oxygen",
                "iri": "http://www.ebi.ac.uk/efo/EFO_0009796",
                "ontology": "efo",
                "synonyms": [],
                "xrefs": []
              },
              {
                "obo_id": "EFO:0004887",
                "label": "maximal oxygen uptake measurement",
                "iri": "http://www.ebi.ac.uk/efo/EFO_0004887",
                "ontology": "efo",
                "synonyms": [],
                "xrefs": []
              },
              {
                "obo_id": "MONDO:0006450",
                "label": "therapy-related myeloid neoplasm",
                "iri": "http://purl.obolibrary.org/obo/MONDO_0006450",
                "ontology": "mondo",
                "synonyms": [],
                "xrefs": []
              },
              {
                "obo_id": "EFO:1000575",
                "label": "Therapy-Related Myeloid Neoplasm",
                "iri": "http://www.ebi.ac.uk/efo/EFO_1000575",
                "ontology": "efo",
                "synonyms": [],
                "xrefs": []
              },
              {
                "obo_id": "HP:0500259",
                "label": "Abnormal oxygen level in cord blood",
                "iri": "http://purl.obolibrary.org/obo/HP_0500259",
                "ontology": "hp",
                "synonyms": [],
                "xrefs": []
              }
            ],
            "best": {
              "obo_id": "EFO:0009796",
              "label": "response to supplemental oxygen",
              "iri": "http://www.ebi.ac.uk/efo/EFO_0009796",
              "ontology": "efo",
              "synonyms": [],
              "xrefs": []
            }
          },
          "ids": [
            "EFO:0009796",
            "EFO:0004887",
            "MONDO:0006450",
            "EFO:1000575",
            "HP:0500259"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": "2",
            "has_more": true
          },
          "source_meta": {
            "source": "ols",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:03.922859Z",
            "data_schema_version": "v1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-005"
            }
          }
        }
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Merged concept candidates into 'drug' pivot.",
          "data": {
            "concept": {
              "label": "sirolimus",
              "type": "drug",
              "pivot": {
                "source": "rxnorm",
                "id": "35302"
              },
              "synonyms": [
                {
                  "text": "1094-61-7",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Nicotinamide ribotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "2KG6QX4W0V",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "DTXSID50911152",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Alpha9",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carbamoyl-1-((2R,3R,4S,5R)-5-((hydrogen phosphonatooxy)methyl)-3,4-dihydroxyoxolan-2-yl)-1$l^(5)-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "ELITEHEALTH",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "REUS NR",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "RefChem:854107",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Mononucleotide, Nicotinamide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "CHEBI:50383",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "DTXCID001511294",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "214-136-5",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carboxy-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-((phosphonooxy)methyl)oxolan-2-yl)-1lambda5-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-Nicotinamide mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "NMN zwitterion",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide nucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-nicotinamide D-ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide D-ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "BETANMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-Nicotinamide ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "MFCD00038748",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-(Aminocarbonyl)-1-(5-O-phosphonato-beta-D-ribofuranosyl)pyridinium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "B-NICOTINAMIDE MONONUCLEOTIDE",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Nicotinamide ribonucleoside 5'-phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-nicotinamide ribose monophosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "b-D-NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "C11H15N2O8P",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "BETA-D-NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "UNII-2KG6QX4W0V",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "reinvigorator",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Fosribnicotinamide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "EINECS 214-136-5",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "ss-NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Nicotine Impurity 9",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Nicotinamidmononucleotid",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "fosribnicotinamide [INN]",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "-NM;NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "bmse000260",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "-Nicotinamide mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "?-Nicotinamidemononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Nicotinamide Mononucleotide?",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "NMN [MI]",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "|A-Nicotinamidemononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "?-Nicotinamide Mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "ss-Nicotinamide mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "fA-Nicotinamide Mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "SCHEMBL105618",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "|_-Nicotinamide Mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "CHEMBL610238",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "orb1302620",
                  "source": "pubchem",
                  "weight": 0.7
                }
              ],
              "xrefs": [
                {
                  "source": "rxnorm",
                  "id": "RxCUI:35302"
                }
              ],
              "warnings": []
            }
          },
          "ids": [
            "35302"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "internal",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:04.126173Z",
            "data_schema_version": "v1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-007"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 3.91,
      "endpoint": null,
      "enabled": true
    },
    {
      "tool": "build_search_terms",
      "payload": {
        "concept": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Merged concept candidates into 'drug' pivot.",
          "data": {
            "concept": {
              "label": "sirolimus",
              "type": "drug",
              "pivot": {
                "source": "rxnorm",
                "id": "35302"
              },
              "synonyms": [
                {
                  "text": "1094-61-7",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Nicotinamide ribotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "2KG6QX4W0V",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "DTXSID50911152",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Alpha9",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carbamoyl-1-((2R,3R,4S,5R)-5-((hydrogen phosphonatooxy)methyl)-3,4-dihydroxyoxolan-2-yl)-1$l^(5)-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "ELITEHEALTH",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "REUS NR",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "RefChem:854107",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Mononucleotide, Nicotinamide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "CHEBI:50383",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "DTXCID001511294",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "214-136-5",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carboxy-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-((phosphonooxy)methyl)oxolan-2-yl)-1lambda5-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-Nicotinamide mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "NMN zwitterion",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide nucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-nicotinamide D-ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide D-ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "BETANMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-Nicotinamide ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "MFCD00038748",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-(Aminocarbonyl)-1-(5-O-phosphonato-beta-D-ribofuranosyl)pyridinium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "B-NICOTINAMIDE MONONUCLEOTIDE",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Nicotinamide ribonucleoside 5'-phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-nicotinamide ribose monophosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "b-D-NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "C11H15N2O8P",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "BETA-D-NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "UNII-2KG6QX4W0V",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "reinvigorator",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Fosribnicotinamide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "EINECS 214-136-5",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "ss-NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Nicotine Impurity 9",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Nicotinamidmononucleotid",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "fosribnicotinamide [INN]",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "-NM;NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "bmse000260",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "-Nicotinamide mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "?-Nicotinamidemononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Nicotinamide Mononucleotide?",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "NMN [MI]",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "|A-Nicotinamidemononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "?-Nicotinamide Mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "ss-Nicotinamide mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "fA-Nicotinamide Mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "SCHEMBL105618",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "|_-Nicotinamide Mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "CHEMBL610238",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "orb1302620",
                  "source": "pubchem",
                  "weight": 0.7
                }
              ],
              "xrefs": [
                {
                  "source": "rxnorm",
                  "id": "RxCUI:35302"
                }
              ],
              "warnings": []
            }
          },
          "ids": [
            "35302"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "internal",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:04.126173Z",
            "data_schema_version": "v1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-007"
            }
          }
        },
        "max_synonyms": 10
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Built controlled search term set with 10 primary term(s).",
          "data": {
            "terms": {
              "pubmed": [
                "sirolimus",
                "1094-61-7",
                "nicotinamide mononucleotide",
                "Nicotinamide ribotide",
                "2KG6QX4W0V",
                "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
                "DTXSID50911152",
                "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
                "Alpha9",
                "((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate"
              ],
              "clinicaltrials": [
                "sirolimus",
                "1094-61-7",
                "nicotinamide mononucleotide",
                "Nicotinamide ribotide",
                "2KG6QX4W0V",
                "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt"
              ],
              "safety": [
                "sirolimus"
              ],
              "expansion": [],
              "exclude": [
                "ageing",
                "aging",
                "compound",
                "drug",
                "intervention",
                "therapy",
                "treatment"
              ]
            },
            "label": "sirolimus",
            "disambiguators": []
          },
          "ids": [
            "sirolimus",
            "1094-61-7",
            "nicotinamide mononucleotide",
            "Nicotinamide ribotide",
            "2KG6QX4W0V",
            "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
            "DTXSID50911152",
            "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
            "Alpha9",
            "((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "internal",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:04.129097Z",
            "data_schema_version": "v1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-008"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 2.31,
      "endpoint": null,
      "enabled": true
    },
    {
      "tool": "normalize_mesh_expand",
      "payload": {
        "query": "rapamycin",
        "limit": 5
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Resolved 3 MeSH descriptor candidate(s) for 'rapamycin'.",
          "data": {
            "query": "rapamycin",
            "records": [
              {
                "mesh_id": "D000076222",
                "label": "Mechanistic Target of Rapamycin Complex 1",
                "entry_terms": [
                  "Mechanistic Target of Rapamycin Complex 1",
                  "TOR Complex 1",
                  "TORC1",
                  "Target of Rapamycin Complex 1",
                  "mTORC1",
                  "mTORC1 Complex"
                ],
                "scope_note": null
              },
              {
                "mesh_id": "D000076225",
                "label": "Mechanistic Target of Rapamycin Complex 2",
                "entry_terms": [
                  "Mechanistic Target of Rapamycin Complex 2",
                  "MTORC-2",
                  "TOR Complex 2",
                  "TORC2",
                  "Target of Rapamycin Complex 2",
                  "mTORC2"
                ],
                "scope_note": null
              },
              {
                "mesh_id": "D000076226",
                "label": "Rapamycin-Insensitive Companion of mTOR Protein",
                "entry_terms": [
                  "Rapamycin-Insensitive Companion of mTOR Protein",
                  "RICTOR Protein"
                ],
                "scope_note": null
              }
            ]
          },
          "ids": [
            "D000076222",
            "D000076225",
            "D000076226"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "mesh_details_D000076222.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/normalize_mesh_expand/manual-009/raw/mesh_details_D000076222.json",
              "sha256": "1b365490ce2f1ebbd364fd68cd5913a1965e0fd0bdc3057f5ae3c6324f25a59c",
              "size_bytes": 3903
            },
            {
              "kind": "raw_json",
              "name": "mesh_details_D000076225.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/normalize_mesh_expand/manual-009/raw/mesh_details_D000076225.json",
              "sha256": "8d20c181d4a0919aa7ee352fd9bef47ca7c62c17471ea0269f3096736f1130fe",
              "size_bytes": 3896
            },
            {
              "kind": "raw_json",
              "name": "mesh_details_D000076226.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/normalize_mesh_expand/manual-009/raw/mesh_details_D000076226.json",
              "sha256": "5a5d644b742f87d776d6745ea1aa7fe5093a9705a383bb5b328f2e33bc28713d",
              "size_bytes": 3398
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "mesh",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:06.553371Z",
            "data_schema_version": "v2.1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-009"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 2426.4,
      "endpoint": "https://id.nlm.nih.gov/mesh/lookup/descriptor",
      "enabled": true
    },
    {
      "tool": "normalize_expand_terms_llm",
      "payload": {
        "concept": {
          "label": "sirolimus",
          "type": "drug",
          "pivot": {
            "source": "rxnorm",
            "id": "35302"
          },
          "synonyms": [
            {
              "text": "1094-61-7",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "nicotinamide mononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Nicotinamide ribotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "2KG6QX4W0V",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "DTXSID50911152",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Alpha9",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "3-carbamoyl-1-((2R,3R,4S,5R)-5-((hydrogen phosphonatooxy)methyl)-3,4-dihydroxyoxolan-2-yl)-1$l^(5)-pyridin-1-ylium",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "ELITEHEALTH",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "REUS NR",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "RefChem:854107",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Mononucleotide, Nicotinamide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "CHEBI:50383",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "DTXCID001511294",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "214-136-5",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "3-carboxy-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-((phosphonooxy)methyl)oxolan-2-yl)-1lambda5-pyridin-1-ylium",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "beta-Nicotinamide mononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "beta-NMN",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "NMN zwitterion",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "NMN",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "nicotinamide nucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "nicotinamide ribonucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "beta-nicotinamide D-ribonucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "nicotinamide D-ribonucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "BETANMN",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "beta-Nicotinamide ribonucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "MFCD00038748",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "3-(Aminocarbonyl)-1-(5-O-phosphonato-beta-D-ribofuranosyl)pyridinium",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "B-NICOTINAMIDE MONONUCLEOTIDE",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Nicotinamide ribonucleoside 5'-phosphate",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "beta-nicotinamide ribose monophosphate",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "b-D-NMN",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "C11H15N2O8P",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "BETA-D-NMN",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "UNII-2KG6QX4W0V",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "reinvigorator",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Fosribnicotinamide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "EINECS 214-136-5",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "ss-NMN",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Nicotine Impurity 9",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Nicotinamidmononucleotid",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "fosribnicotinamide [INN]",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "-NM;NMN",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "bmse000260",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "-Nicotinamide mononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "?-Nicotinamidemononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Nicotinamide Mononucleotide?",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "NMN [MI]",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "|A-Nicotinamidemononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "?-Nicotinamide Mononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "ss-Nicotinamide mononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "fA-Nicotinamide Mononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "SCHEMBL105618",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "|_-Nicotinamide Mononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "CHEMBL610238",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "orb1302620",
              "source": "pubchem",
              "weight": 0.7
            }
          ],
          "xrefs": [
            {
              "source": "rxnorm",
              "id": "RxCUI:35302"
            }
          ],
          "warnings": []
        },
        "mode": "balanced",
        "max_exact_synonyms": 8,
        "max_related_terms": 5,
        "llm_suggestions": {
          "exact_synonyms": [
            "sirolimus",
            "rapa"
          ],
          "related_terms": [
            "mTOR inhibitor",
            "mTOR pathway"
          ],
          "disambiguators": [
            "mTOR",
            "aging"
          ],
          "excluded_terms": [
            "drug",
            "therapy"
          ],
          "reasoning_notes": "Seeded deterministic expansion for validation run."
        }
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Expanded normalized terms with guarded synonym logic (balanced).",
          "data": {
            "concept_label": "sirolimus",
            "mode": "balanced",
            "exact_synonyms": [
              {
                "term": "sirolimus",
                "confidence": 0.9
              },
              {
                "term": "1094-61-7",
                "confidence": 0.8
              },
              {
                "term": "nicotinamide mononucleotide",
                "confidence": 0.8
              },
              {
                "term": "Nicotinamide ribotide",
                "confidence": 0.8
              },
              {
                "term": "2KG6QX4W0V",
                "confidence": 0.8
              },
              {
                "term": "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
                "confidence": 0.8
              },
              {
                "term": "DTXSID50911152",
                "confidence": 0.8
              },
              {
                "term": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
                "confidence": 0.8
              }
            ],
            "related_terms": [
              {
                "term": "mTOR inhibitor",
                "confidence": 0.6
              },
              {
                "term": "mTOR pathway",
                "confidence": 0.6
              }
            ],
            "disambiguators": [
              "mTOR",
              "aging"
            ],
            "excluded_terms": [
              "drug",
              "therapy"
            ],
            "reasoning_notes": "Seeded deterministic expansion for validation run."
          },
          "ids": [
            "sirolimus",
            "1094-61-7",
            "nicotinamide mononucleotide",
            "Nicotinamide ribotide",
            "2KG6QX4W0V",
            "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
            "DTXSID50911152",
            "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate"
          ],
          "citations": [],
          "warnings": [
            "Short acronyms (1-2 chars) are filtered unless explicitly disambiguated."
          ],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "internal",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:06.558482Z",
            "data_schema_version": "v2.1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-010"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 2.9,
      "endpoint": "internal",
      "enabled": true
    },
    {
      "tool": "pubmed_search",
      "payload": {
        "query": "(rapamycin OR sirolimus) AND aging",
        "limit": 10
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Retrieved 10 PMID(s) for PubMed query.",
          "data": {
            "term": "(rapamycin OR sirolimus) AND aging",
            "count": 3336,
            "pmids": [
              "33037985",
              "33981041",
              "31761958",
              "39951177",
              "37142830",
              "24508508",
              "38126098",
              "25015322",
              "38310895",
              "39779911"
            ],
            "query_translation": "(\"rapamycin s\"[All Fields] OR \"rapamycine\"[All Fields] OR \"rapamycins\"[All Fields] OR \"sirolimus\"[Supplementary Concept] OR \"sirolimus\"[All Fields] OR \"rapamycin\"[All Fields] OR \"sirolimus\"[MeSH Terms] OR (\"sirolimus\"[Supplementary Concept] OR \"sirolimus\"[All Fields] OR \"sirolimus\"[MeSH Terms])) AND (\"aging\"[MeSH Terms] OR \"aging\"[All Fields] OR \"ageing\"[All Fields])",
            "webenv": "MCID_69a2635bb39f959fd30c2633",
            "query_key": "1",
            "query": "(rapamycin OR sirolimus) AND aging"
          },
          "ids": [
            "33037985",
            "33981041",
            "31761958",
            "39951177",
            "37142830",
            "24508508",
            "38126098",
            "25015322",
            "38310895",
            "39779911"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "pubmed_esearch.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/pubmed_search/manual-011/raw/pubmed_esearch.json",
              "sha256": "f7db100439b903c429732329442bd340c82438189fad9788622ad94fcadd2187",
              "size_bytes": 1440
            }
          ],
          "pagination": {
            "next_page_token": "10",
            "has_more": true
          },
          "source_meta": {
            "source": "pubmed",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:07.612041Z",
            "data_schema_version": "v2.1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-011"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 1054.2,
      "endpoint": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi",
      "enabled": true
    },
    {
      "tool": "pubmed_fetch",
      "payload": {
        "ids": [
          "33037985",
          "33981041",
          "31761958",
          "39951177",
          "37142830"
        ],
        "include_classification_fields": true
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Fetched 5 PubMed record(s).",
          "data": {
            "records": [
              {
                "pmid": "33037985",
                "title": "Effect of rapamycin on aging and age-related diseases-past and future.",
                "abstract": "In 2009, rapamycin was reported to increase the lifespan of mice when implemented later in life. This observation resulted in a sea-change in how researchers viewed aging. This was the first evidence that a pharmacological agent could have an impact on aging when administered later in life, i.e., an intervention that did not have to be implemented early in life before the negative impact of aging. Over the past decade, there has been an explosion in the number of reports studying the effect of rapamycin on various diseases, physiological functions, and biochemical processes in mice. In this review, we focus on those areas in which there is strong evidence for rapamycin's effect on aging and age-related diseases in mice, e.g., lifespan, cardiac disease/function, central nervous system, immune system, and cell senescence. We conclude that it is time that pre-clinical studies be focused on taking rapamycin to the clinic, e.g., as a potential treatment for Alzheimer's disease.",
                "publication_types": [
                  "Journal Article",
                  "Research Support, N.I.H., Extramural",
                  "Research Support, Non-U.S. Gov't",
                  "Research Support, U.S. Gov't, Non-P.H.S.",
                  "Review"
                ],
                "mesh_terms": [
                  "Aging",
                  "Animals",
                  "Longevity",
                  "Mice",
                  "Sirolimus"
                ],
                "journal": "GeroScience",
                "pub_date": "2021 Jun",
                "publication_year": 2021,
                "doi": "10.1007/s11357-020-00274-1",
                "nct_ids": [],
                "humans": false,
                "animals": true,
                "is_meta_or_systematic": false,
                "is_rct_like": false
              },
              {
                "pmid": "33981041",
                "title": "An aged immune system drives senescence and ageing of solid organs.",
                "abstract": "Ageing of the immune system, or immunosenescence, contributes to the morbidity and mortality of the elderly1,2. To define the contribution of immune system ageing to organism ageing, here we selectively deleted Ercc1, which encodes a crucial DNA repair protein3,4, in mouse haematopoietic cells to increase the burden of endogenous DNA damage and thereby senescence5-7 in the immune system only. We show that Vav-iCre+/-;Ercc1-/fl mice were healthy into adulthood, then displayed premature onset of immunosenescence characterized by attrition and senescence of specific immune cell populations and impaired immune function, similar to changes that occur during ageing in wild-type mice8-10. Notably, non-lymphoid organs also showed increased senescence and damage, which suggests that senescent, aged immune cells can promote systemic ageing. The transplantation of splenocytes from Vav-iCre+/-;Ercc1-/fl or aged wild-type mice into young mice induced senescence in trans, whereas the transplantation of young immune cells attenuated senescence. The treatment of Vav-iCre+/-;Ercc1-/fl mice with rapamycin reduced markers of senescence in immune cells and improved immune function11,12. These data demonstrate that an aged, senescent immune system has a causal role in driving systemic ageing and therefore represents a key therapeutic target to extend healthy ageing.",
                "publication_types": [
                  "Journal Article",
                  "Research Support, N.I.H., Extramural",
                  "Research Support, Non-U.S. Gov't"
                ],
                "mesh_terms": [
                  "Aging",
                  "Animals",
                  "DNA Damage",
                  "DNA Repair",
                  "DNA-Binding Proteins",
                  "Endonucleases",
                  "Female",
                  "Healthy Aging",
                  "Homeostasis",
                  "Immune System",
                  "Immunosenescence",
                  "Male",
                  "Mice",
                  "Organ Specificity",
                  "Rejuvenation",
                  "Sirolimus",
                  "Spleen"
                ],
                "journal": "Nature",
                "pub_date": "2021 Jun",
                "publication_year": 2021,
                "doi": "10.1038/s41586-021-03547-7",
                "nct_ids": [],
                "humans": false,
                "animals": true,
                "is_meta_or_systematic": false,
                "is_rct_like": false
              },
              {
                "pmid": "31761958",
                "title": "Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial.",
                "abstract": "Aging is a major risk factor for the majority of human diseases, and the development of interventions to reduce the intrinsic rate of aging is expected to reduce the risk for age-related diseases including cardiovascular disease, cancer, and dementia. In the skin, aging manifests itself in photodamage and dermal atrophy, with underlying tissue reduction and impaired barrier function. To determine whether rapamycin, an FDA-approved drug targeting the mechanistic target of rapamycin (mTOR) complex, can reduce senescence and markers of aging in human skin, an exploratory, placebo-controlled, interventional trial was conducted in a clinical dermatology setting. Participants were greater than 40 years of age with evidence of age-related photoaging and dermal volume loss and no major morbidities. Thirty-six participants were enrolled in the study, and nineteen discontinued or were lost to follow-up. A significant (P = 0.008) reduction in p16INK4A protein levels and an increase in collagen VII protein levels (P = 0.0077) were observed among participants at the end of the study. Clinical improvement in skin appearance was noted in multiple participants, and immunohistochemical analysis revealed improvement in histological appearance of skin tissue. Topical rapamycin reduced the expression of the p16INK4A protein consistent with a reduction in cellular senescence. This change was accompanied by relative improvement in clinical appearance of the skin and histological markers of aging and by an increase in collagen VII, which is critical to the integrity of the basement membrane. These results indicate that rapamycin treatment is a potential anti-aging therapy with efficacy in humans.Trial registration ClinicalTrials.gov Identifier: NCT03103893.",
                "publication_types": [
                  "Journal Article",
                  "Randomized Controlled Trial"
                ],
                "mesh_terms": [
                  "Administration, Topical",
                  "Adult",
                  "Biopsy",
                  "Cellular Senescence",
                  "Collagen Type VII",
                  "Cyclin-Dependent Kinase Inhibitor p16",
                  "Female",
                  "Humans",
                  "Immunohistochemistry",
                  "Immunosuppressive Agents",
                  "Male",
                  "Middle Aged",
                  "Prospective Studies",
                  "Sirolimus",
                  "Skin",
                  "Skin Aging",
                  "Skin Diseases"
                ],
                "journal": "GeroScience",
                "pub_date": "2019 Dec",
                "publication_year": 2019,
                "doi": "10.1007/s11357-019-00113-y",
                "nct_ids": [
                  "NCT03103893"
                ],
                "humans": true,
                "animals": false,
                "is_meta_or_systematic": false,
                "is_rct_like": true
              },
              {
                "pmid": "39951177",
                "title": "Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project.",
                "abstract": "Companion dogs are a powerful model for aging research given their morphologic and genetic variability, risk for age-related disease, and habitation of the human environment. In addition, the shorter life expectancy of dogs compared to human beings provides a unique opportunity for an accelerated timeline to test interventions that might extend healthy lifespan. The Test of Rapamycin In Aging Dogs (TRIAD) randomized clinical trial is a parallel-group, double-masked, randomized, placebo-controlled, multicenter trial that will test the ability of rapamycin to prolong lifespan and improve several healthspan metrics in healthy, middle-aged dogs recruited from Dog Aging Project participants. Here, we describe the rationale, design, and goals of the TRIAD randomized clinical trial, the first rigorous test of a pharmacologic intervention against biological aging with lifespan and healthspan metrics as endpoints to be performed outside of the laboratory in any species.",
                "publication_types": [
                  "Clinical Trial Protocol",
                  "Journal Article"
                ],
                "mesh_terms": [
                  "Animals",
                  "Dogs",
                  "Female",
                  "Male",
                  "Aging",
                  "Double-Blind Method",
                  "Longevity",
                  "Prospective Studies",
                  "Sirolimus",
                  "Randomized Controlled Trials as Topic",
                  "Multicenter Studies as Topic"
                ],
                "journal": "GeroScience",
                "pub_date": "2025 Jun",
                "publication_year": 2025,
                "doi": "10.1007/s11357-024-01484-7",
                "nct_ids": [],
                "humans": false,
                "animals": true,
                "is_meta_or_systematic": false,
                "is_rct_like": true
              },
              {
                "pmid": "37142830",
                "title": "Targeting the biology of aging with mTOR inhibitors.",
                "abstract": "Inhibition of the protein kinase mechanistic target of rapamycin (mTOR) with the Food and Drug Administration (FDA)-approved therapeutic rapamycin promotes health and longevity in diverse model organisms. More recently, specific inhibition of mTORC1 to treat aging-related conditions has become the goal of basic and translational scientists, clinicians and biotechnology companies. Here, we review the effects of rapamycin on the longevity and survival of both wild-type mice and mouse models of human diseases. We discuss recent clinical trials that have explored whether existing mTOR inhibitors can safely prevent, delay or treat multiple diseases of aging. Finally, we discuss how new molecules may provide routes to the safer and more selective inhibition of mTOR complex 1 (mTORC1) in the decade ahead. We conclude by discussing what work remains to be done and the questions that will need to be addressed to make mTOR inhibitors part of the standard of care for diseases of aging.",
                "publication_types": [
                  "Journal Article",
                  "Review",
                  "Research Support, N.I.H., Extramural",
                  "Research Support, Non-U.S. Gov't"
                ],
                "mesh_terms": [
                  "Animals",
                  "Humans",
                  "Mice",
                  "Aging",
                  "Biology",
                  "Mechanistic Target of Rapamycin Complex 1",
                  "MTOR Inhibitors",
                  "Sirolimus",
                  "TOR Serine-Threonine Kinases",
                  "United States"
                ],
                "journal": "Nature aging",
                "pub_date": "2023 Jun",
                "publication_year": 2023,
                "doi": "10.1038/s43587-023-00416-y",
                "nct_ids": [],
                "humans": true,
                "animals": true,
                "is_meta_or_systematic": false,
                "is_rct_like": false
              }
            ]
          },
          "ids": [
            "33037985",
            "33981041",
            "31761958",
            "39951177",
            "37142830"
          ],
          "citations": [
            {
              "pmid": "33037985",
              "doi": "10.1007/s11357-020-00274-1",
              "title": "Effect of rapamycin on aging and age-related diseases-past and future.",
              "year": 2021
            },
            {
              "pmid": "33981041",
              "doi": "10.1038/s41586-021-03547-7",
              "title": "An aged immune system drives senescence and ageing of solid organs.",
              "year": 2021
            },
            {
              "pmid": "31761958",
              "doi": "10.1007/s11357-019-00113-y",
              "title": "Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial.",
              "year": 2019
            },
            {
              "pmid": "39951177",
              "doi": "10.1007/s11357-024-01484-7",
              "title": "Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project.",
              "year": 2025
            },
            {
              "pmid": "37142830",
              "doi": "10.1038/s43587-023-00416-y",
              "title": "Targeting the biology of aging with mTOR inhibitors.",
              "year": 2023
            }
          ],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "pubmed_fetch.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/pubmed_fetch/manual-012/raw/pubmed_fetch.json",
              "sha256": "315a9ab1fc9868c8230ad90246688160555d718e33e86369684504026a389356",
              "size_bytes": 321875
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "pubmed",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:08.820252Z",
            "data_schema_version": "v2.1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-012"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 1207.66,
      "endpoint": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi",
      "enabled": true
    },
    {
      "tool": "pubmed_enrich_pmids",
      "payload": {
        "pmids": [
          "31452104",
          "31919194"
        ]
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Enriched 2 PMID record(s) from PubMed metadata.",
          "data": {
            "records": [
              {
                "pmid": "31452104",
                "title": "Molegro Virtual Docker for Docking.",
                "pubdate": "2019",
                "source": "Methods Mol Biol",
                "pub_types": [
                  "Journal Article",
                  "Research Support, Non-U.S. Gov't"
                ],
                "publication_types": [
                  "Journal Article",
                  "Research Support, Non-U.S. Gov't"
                ],
                "article_ids": [
                  {
                    "idtype": "pubmed",
                    "idtypen": 1,
                    "value": "31452104"
                  },
                  {
                    "idtype": "doi",
                    "idtypen": 3,
                    "value": "10.1007/978-1-4939-9752-7_10"
                  }
                ],
                "doi": "10.1007/978-1-4939-9752-7_10",
                "publication_year": 2019,
                "is_meta_or_systematic": false,
                "is_rct_like": false
              },
              {
                "pmid": "31919194",
                "title": "ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma.",
                "pubdate": "2020 Jan",
                "source": "Eur Respir J",
                "pub_types": [
                  "Editorial",
                  "Research Support, Non-U.S. Gov't"
                ],
                "publication_types": [
                  "Editorial",
                  "Research Support, Non-U.S. Gov't"
                ],
                "article_ids": [
                  {
                    "idtype": "pubmed",
                    "idtypen": 1,
                    "value": "31919194"
                  },
                  {
                    "idtype": "doi",
                    "idtypen": 3,
                    "value": "10.1183/13993003.01407-2019"
                  },
                  {
                    "idtype": "pii",
                    "idtypen": 4,
                    "value": "55/1/1901407"
                  }
                ],
                "doi": "10.1183/13993003.01407-2019",
                "publication_year": 2020,
                "is_meta_or_systematic": false,
                "is_rct_like": false
              }
            ]
          },
          "ids": [
            "31452104",
            "31919194"
          ],
          "citations": [
            {
              "pmid": "31452104",
              "doi": "10.1007/978-1-4939-9752-7_10",
              "title": "Molegro Virtual Docker for Docking.",
              "year": 2019
            },
            {
              "pmid": "31919194",
              "doi": "10.1183/13993003.01407-2019",
              "title": "ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma.",
              "year": 2020
            }
          ],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "pubmed_esummary.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/pubmed_enrich_pmids/manual-013/raw/pubmed_esummary.json",
              "sha256": "c275610e9f2100c0ab0b6d7e3343dedc91481f5444d55a43474d0f1b05de2eb2",
              "size_bytes": 5944
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "pubmed",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:09.402467Z",
            "data_schema_version": "v1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-013"
            }
          }
        }
      },
      "note": "PMID enrichment only",
      "latency_ms": 582.19,
      "endpoint": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi",
      "enabled": true
    },
    {
      "tool": "europmc_search",
      "payload": {
        "query": "rapamycin aging",
        "page_size": 5
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Retrieved 5 Europe PMC record(s).",
          "data": {
            "query": "rapamycin aging",
            "records": [
              {
                "id": "PMID:41707042",
                "title": "Short-Term Rapamycin Mitigates the Senescence of Ovaries and Somatic Stem Cells in Multiple Organs in Reproductively Aged Mice.",
                "publication_year": 2026,
                "source": "MED",
                "pmid": "41707042",
                "pmcid": null,
                "doi": "10.1096/fj.202504132r",
                "journal": null,
                "author_string": "Lu J, Li J, Liu C, Feng G, Yin G, Hu Z, Heng D, Yu Y, Jin K, Wu Y, Feng Z, Chen J, Wei Y, Wang Y, Hu X, Liu L, Du X, Zhu Z.",
                "is_open_access": false,
                "abstract_snippet": "Reproductive aging in females is marked by ovarian senescence and a concomitant decline in somatic organ function. Mechanistic target of rapamycin (mTOR) signaling is a central regulator of aging. Rapamycin has been shown to confer anti-aging benefits in young and middle-aged females; however, whether mTOR inhibition remains effective once reproductive aging is established remains unclear. Here we"
              },
              {
                "id": "PMID:41653162",
                "title": "Rapamycin Reverses the Hepatic Response to Diet-Induced Metabolic Stress That Is Amplified by Aging.",
                "publication_year": 2026,
                "source": "MED",
                "pmid": "41653162",
                "pmcid": "PMC12882742",
                "doi": "10.1111/acel.70395",
                "journal": null,
                "author_string": "Havas A, Rajesh A, Lei X, Proulx J, Miller KN, Field A, Davis A, Teneche MG, Gandhi A, Lee J, Feng GS, Adams PD.",
                "is_open_access": true,
                "abstract_snippet": "Aging is associated with increased susceptibility to metabolic stress and chronic liver disease, yet the interactions between age and metabolic stressors and the potential for ameliorating interventions remain incompletely understood. Here, we examined the hepatic response of young (7-month-old) and old (25-month-old) C57BL/6 male mice to a 9-week high-fat diet (HFD) and assessed whether rapamycin"
              },
              {
                "id": "DOI:10.32942/x25h23",
                "title": "Integrating evolutionary theory into a framework for the mechanistic evaluation of candidate anti-aging interventions",
                "publication_year": 2026,
                "source": "PPR",
                "pmid": null,
                "pmcid": null,
                "doi": "10.32942/x25h23",
                "journal": null,
                "author_string": "Aggour Y, Salguero-Gomez R.",
                "is_open_access": false,
                "abstract_snippet": "Despite decades of research into the molecular hallmarks of aging, geroscience lacks a unifying framework to guide the development of effective anti-aging interventions. Here, we integrate two leading evolutionary theoriesthe Disposable Soma Theory and Hyperfunction Theoryinto a layered model of aging biology, the Aging Onion. In this framework, aging arises both from persistent activity of gr"
              },
              {
                "id": "PMCID:PMC12937842",
                "title": "Mechanistic Links Between the Gut Microbiome and Longevity Therapeutics",
                "publication_year": 2026,
                "source": "PMC",
                "pmid": null,
                "pmcid": "PMC12937842",
                "doi": null,
                "journal": null,
                "author_string": null,
                "is_open_access": true,
                "abstract_snippet": null
              },
              {
                "id": "PMCID:PMC12759609",
                "title": "Testing the Translational Potential of Rapamycin on Healthy Aging",
                "publication_year": 2025,
                "source": "PMC",
                "pmid": null,
                "pmcid": "PMC12759609",
                "doi": null,
                "journal": null,
                "author_string": null,
                "is_open_access": true,
                "abstract_snippet": null
              }
            ],
            "hit_count": 33182,
            "page": 1
          },
          "ids": [
            "PMID:41707042",
            "PMID:41653162",
            "DOI:10.32942/x25h23",
            "PMCID:PMC12937842",
            "PMCID:PMC12759609"
          ],
          "citations": [
            {
              "pmid": "41707042",
              "pmcid": null,
              "doi": "10.1096/fj.202504132r",
              "title": "Short-Term Rapamycin Mitigates the Senescence of Ovaries and Somatic Stem Cells in Multiple Organs in Reproductively Aged Mice.",
              "year": 2026
            },
            {
              "pmid": "41653162",
              "pmcid": "PMC12882742",
              "doi": "10.1111/acel.70395",
              "title": "Rapamycin Reverses the Hepatic Response to Diet-Induced Metabolic Stress That Is Amplified by Aging.",
              "year": 2026
            },
            {
              "pmid": null,
              "pmcid": null,
              "doi": "10.32942/x25h23",
              "title": "Integrating evolutionary theory into a framework for the mechanistic evaluation of candidate anti-aging interventions",
              "year": 2026
            },
            {
              "pmid": null,
              "pmcid": "PMC12937842",
              "doi": null,
              "title": "Mechanistic Links Between the Gut Microbiome and Longevity Therapeutics",
              "year": 2026
            },
            {
              "pmid": null,
              "pmcid": "PMC12759609",
              "doi": null,
              "title": "Testing the Translational Potential of Rapamycin on Healthy Aging",
              "year": 2025
            }
          ],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "europmc_search_page_1.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/europmc_search/manual-014/raw/europmc_search_page_1.json",
              "sha256": "6696bc5823d306b44952c6052753bd9b1fdb45ed58445045b87c69d5a753468a",
              "size_bytes": 47691
            }
          ],
          "pagination": {
            "next_page_token": "2",
            "has_more": true
          },
          "source_meta": {
            "source": "europmc",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:09.679485Z",
            "data_schema_version": "v2.1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-014"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 277.45,
      "endpoint": "https://www.ebi.ac.uk/europepmc/webservices/rest/search",
      "enabled": true
    },
    {
      "tool": "clinicaltrials_search_studies",
      "payload": {
        "intr": "rapamycin",
        "cond": "aging",
        "page_size": 5
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Retrieved 5 ClinicalTrials.gov study record(s).",
          "data": {
            "query": null,
            "intervention": "rapamycin",
            "condition": "aging",
            "studies": [
              {
                "nct_id": "NCT06658093",
                "brief_title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
                "official_title": "RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects",
                "overall_status": "RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "EARLY_PHASE1"
                ],
                "enrollment": 194,
                "primary_outcomes": [
                  {
                    "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                    "description": "The levels of the study drug will be measured in whole blood",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                    "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                    "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                    "timeFrame": "Baseline to study end (approximately 12 months)"
                  }
                ],
                "primary_completion_date": "2028-07",
                "completion_date": "2028-07",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Age 65 to 90 years 2. Men and women 3. In good health with all medical problems stable. 4. Community-dwelling 5. Agreement to adhere to Lifestyle Considerations throughout study duration. 6. Ability of participant to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Resident of nursing home or long-term care f",
                "arms_count": 0,
                "has_results": false
              },
              {
                "nct_id": "NCT05836025",
                "brief_title": "Effect of Rapamycin in Ovarian Aging",
                "official_title": "Effect of Rapamycin in Ovarian Aging",
                "overall_status": "ACTIVE_NOT_RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "PHASE2"
                ],
                "enrollment": 50,
                "primary_outcomes": [
                  {
                    "measure": "Measure of Ovarian Reserve",
                    "description": "Ovarian reserve will be determined using AMH",
                    "timeFrame": "Up to 1 year"
                  }
                ],
                "primary_completion_date": "2025-10-21",
                "completion_date": "2026-09",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: * Women aged 35-45 years * In the menopausal transition stage -3a * Have been unable to conceive based on diminished ovarian reserve and who have failed to develop any euploid embryos with IVF or who do not desire to conceive within the next 1.5 years * Have regular menstrual periods (with less than 7 days of variability) * Early follicular phase follicle stimulating hormone (FSH) levels \\] \\< 20 mIU/mL * Anti-mllerian hormone (AMH) levels of \\>0.1 ng/mL * Antral Follicle Co",
                "arms_count": 0,
                "has_results": false
              },
              {
                "nct_id": "NCT07092618",
                "brief_title": "Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation",
                "official_title": "Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation: A Randomized, Controlled Trial",
                "overall_status": "RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "PHASE2",
                  "PHASE3"
                ],
                "enrollment": 150,
                "primary_outcomes": [
                  {
                    "measure": "Evaluate the effectiveness of metformin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic or Wegovy (or compounded semaglutide equivalent)",
                    "description": "Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline.\n\n1. Individuals that maintain the relative weight over the course of six months post-GLP-1 receptor agonist cessation\n2. Individuals that have less weight gain over the course of six months post-GLP-1 receptor agonist cessation using the combinatorial therapies than those who do not",
                    "timeFrame": "6 months"
                  },
                  {
                    "measure": "Evaluate the effectiveness of metformin + rapamycin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent)",
                    "description": "Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline.",
                    "timeFrame": "6 months"
                  },
                  {
                    "measure": "Evaluate the effectiveness of metformin + LDN in maintaining GLP1-induced weight loss in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent)",
                    "description": "Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline.",
                    "timeFrame": "6 months"
                  }
                ],
                "primary_completion_date": "2025-08",
                "completion_date": "2025-08",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: * Existing AgelessRx patient * Adults (40 - 85 years of age) * Any sex * Any ethnicity * BMI  22 kg/m\\^2 * Have been on GLP-1s (Wegovy, Ozempic, or a compounded form of GLP-1s) for at least three months before study initiation * Have lost at least 15 lbs during their GLP-1 use Exclusion Criteria: * Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s) * History of bari",
                "arms_count": 0,
                "has_results": false
              },
              {
                "nct_id": "NCT07058974",
                "brief_title": "A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation",
                "official_title": "A Phase 1b, Multi-cohort Clinical Trial Assessing Safety and Feasibility of Exercise and Spermidine Administered in Conjunction With Lamivudine (RTi) or Rapamycin (mTORi) to Assess Impact on Dynamic Changes of Inflammation and Aging",
                "overall_status": "RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "PHASE1"
                ],
                "enrollment": 22,
                "primary_outcomes": [
                  {
                    "measure": "Number and Type of Grade 3/4 Adverse Events per CTCAE Version 5.0",
                    "description": "Number and Type of Grade 3/4 Adverse Events per CTCAE Version 5.0. Toxicity will be assessed according to the Common Toxicity Criteria for Adverse Events (CTCAE), version 5.0. Any patient experiencing a Grade 3 or 4 adverse event must hold drug until toxicity returns to grade 0-1. The treating investigator may hold study drug for any duration if the patient is deemed to be experiencing a Grade 1-2 adverse event related to study drug.",
                    "timeFrame": "at 180 days"
                  },
                  {
                    "measure": "Number of participants with ability to complete >80% of specified pharmacological intervention",
                    "description": "Feasibility of the trial is determined by participant documentation of taking at least 80% of the provided study drug on a regular basis, ability to complete \\>80% of specified pharmacological intervention.",
                    "timeFrame": "at 180 days"
                  }
                ],
                "primary_completion_date": "2026-07-01",
                "completion_date": "2026-07-01",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: * Patients 65-80 years old * Current or former smokers * BMI 25-32 * No cancer requiring active therapy within the last 2 years * No autoimmune disease requiring disease modifying agents * No patients with CKD stage 3/4 or ESRD * No class 3 or 4 heart failure Exclusion Criteria: * Patients may not have cancer requiring active therapy within the last 2 years * Patients may not have autoimmune disease requiring disease modifying agents * Patients may not be receiving immune mod",
                "arms_count": 0,
                "has_results": false
              },
              {
                "nct_id": "NCT07191353",
                "brief_title": "Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women",
                "official_title": "Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women",
                "overall_status": "NOT_YET_RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "PHASE2"
                ],
                "enrollment": 148,
                "primary_outcomes": [
                  {
                    "measure": "P1NP",
                    "description": "Percentage change in circulating levels of bone formation marker N-terminal fragment of procollagen type 1 (P1NP) at 24 weeks as compared with baseline",
                    "timeFrame": "From baseline to end of treatment at 24 weeks"
                  }
                ],
                "primary_completion_date": "2027-03-01",
                "completion_date": "2027-03-01",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: * Women aged 60-75 years old, any ethnicity. * Participants with T- score between \\< 1.0 and \\> -2.5 measured by DXA scan within 6 months of the first day of the study. * Adequate cognitive function to be able to give informed consent. Exclusion Criteria: * Osteoporosis and fracture history * Participants with osteoporosis (defined by DXA scan \\< 6 months old: low bone mass, T-score \\< -2.5 or hip fracture or clinical compression fracture of the spine). * History of low energ",
                "arms_count": 0,
                "has_results": false
              }
            ]
          },
          "ids": [
            "NCT06658093",
            "NCT05836025",
            "NCT07092618",
            "NCT07058974",
            "NCT07191353"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "clinicaltrials_search.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/clinicaltrials_search_studies/manual-015/raw/clinicaltrials_search.json",
              "sha256": "aea3e8afe04167ddea82547582f4ac04824a065e29384e38c8d06f8962da326e",
              "size_bytes": 100285
            }
          ],
          "pagination": {
            "next_page_token": "ZVNj7o2Elu8o3lpoCMr95LrumpOQJJxuYfKs2vAYkA",
            "has_more": true
          },
          "source_meta": {
            "source": "clinicaltrials",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:10.011297Z",
            "data_schema_version": "v2.1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-015"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 331.57,
      "endpoint": "https://clinicaltrials.gov/api/v2/studies",
      "enabled": true
    },
    {
      "tool": "clinicaltrials_get_studies",
      "payload": {
        "nct_ids": [
          "NCT06658093",
          "NCT05836025",
          "NCT07092618"
        ]
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Fetched 3 ClinicalTrials.gov study detail record(s).",
          "data": {
            "studies": [
              {
                "nct_id": "NCT06658093",
                "brief_title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
                "official_title": "RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects",
                "overall_status": "RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "EARLY_PHASE1"
                ],
                "enrollment": 194,
                "primary_outcomes": [
                  {
                    "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                    "description": "The levels of the study drug will be measured in whole blood",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                    "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                    "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                    "timeFrame": "Baseline to study end (approximately 12 months)"
                  }
                ],
                "primary_completion_date": "2028-07",
                "completion_date": "2028-07",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Age 65 to 90 years 2. Men and women 3. In good health with all medical problems stable. 4. Community-dwelling 5. Agreement to adhere to Lifestyle Considerations throughout study duration. 6. Ability of participant to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Resident of nursing home or long-term care f",
                "arms_count": 0,
                "has_results": false
              },
              {
                "nct_id": "NCT05836025",
                "brief_title": "Effect of Rapamycin in Ovarian Aging",
                "official_title": "Effect of Rapamycin in Ovarian Aging",
                "overall_status": "ACTIVE_NOT_RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "PHASE2"
                ],
                "enrollment": 50,
                "primary_outcomes": [
                  {
                    "measure": "Measure of Ovarian Reserve",
                    "description": "Ovarian reserve will be determined using AMH",
                    "timeFrame": "Up to 1 year"
                  }
                ],
                "primary_completion_date": "2025-10-21",
                "completion_date": "2026-09",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: * Women aged 35-45 years * In the menopausal transition stage -3a * Have been unable to conceive based on diminished ovarian reserve and who have failed to develop any euploid embryos with IVF or who do not desire to conceive within the next 1.5 years * Have regular menstrual periods (with less than 7 days of variability) * Early follicular phase follicle stimulating hormone (FSH) levels \\] \\< 20 mIU/mL * Anti-mllerian hormone (AMH) levels of \\>0.1 ng/mL * Antral Follicle Co",
                "arms_count": 0,
                "has_results": false
              },
              {
                "nct_id": "NCT07092618",
                "brief_title": "Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation",
                "official_title": "Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation: A Randomized, Controlled Trial",
                "overall_status": "RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "PHASE2",
                  "PHASE3"
                ],
                "enrollment": 150,
                "primary_outcomes": [
                  {
                    "measure": "Evaluate the effectiveness of metformin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic or Wegovy (or compounded semaglutide equivalent)",
                    "description": "Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline.\n\n1. Individuals that maintain the relative weight over the course of six months post-GLP-1 receptor agonist cessation\n2. Individuals that have less weight gain over the course of six months post-GLP-1 receptor agonist cessation using the combinatorial therapies than those who do not",
                    "timeFrame": "6 months"
                  },
                  {
                    "measure": "Evaluate the effectiveness of metformin + rapamycin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent)",
                    "description": "Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline.",
                    "timeFrame": "6 months"
                  },
                  {
                    "measure": "Evaluate the effectiveness of metformin + LDN in maintaining GLP1-induced weight loss in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent)",
                    "description": "Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline.",
                    "timeFrame": "6 months"
                  }
                ],
                "primary_completion_date": "2025-08",
                "completion_date": "2025-08",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: * Existing AgelessRx patient * Adults (40 - 85 years of age) * Any sex * Any ethnicity * BMI  22 kg/m\\^2 * Have been on GLP-1s (Wegovy, Ozempic, or a compounded form of GLP-1s) for at least three months before study initiation * Have lost at least 15 lbs during their GLP-1 use Exclusion Criteria: * Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s) * History of bari",
                "arms_count": 0,
                "has_results": false
              }
            ],
            "include_raw": false
          },
          "ids": [
            "NCT06658093",
            "NCT05836025",
            "NCT07092618"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "clinicaltrials_NCT06658093.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/clinicaltrials_get_studies/manual-016/raw/clinicaltrials_NCT06658093.json",
              "sha256": "4482a1a06dd9fca7a81621f6c813247b3bb6469af4c723696e13547897c0b016",
              "size_bytes": 23444
            },
            {
              "kind": "raw_json",
              "name": "clinicaltrials_NCT05836025.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/clinicaltrials_get_studies/manual-016/raw/clinicaltrials_NCT05836025.json",
              "sha256": "e76dbf4d6f924c8f2159db65c3c9e8eabc2ecde7d14d71f14bbafcb52c3b7d50",
              "size_bytes": 8450
            },
            {
              "kind": "raw_json",
              "name": "clinicaltrials_NCT07092618.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/clinicaltrials_get_studies/manual-016/raw/clinicaltrials_NCT07092618.json",
              "sha256": "50fe1815fe8b09b1bb0b79730a21b8f4f0f6a44f519fbf89362ad7adf8a660a0",
              "size_bytes": 23188
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "clinicaltrials",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:10.773123Z",
            "data_schema_version": "v2.1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-016"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 762.03,
      "endpoint": "https://clinicaltrials.gov/api/v2/studies/{nct_id}",
      "enabled": true
    },
    {
      "tool": "clinicaltrials_fetch",
      "payload": {
        "ids": [
          "NCT06658093",
          "NCT05836025",
          "NCT07092618"
        ],
        "include_raw": false
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Fetched 3 ClinicalTrials.gov study detail record(s).",
          "data": {
            "studies": [
              {
                "nct_id": "NCT06658093",
                "brief_title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
                "official_title": "RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects",
                "overall_status": "RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "EARLY_PHASE1"
                ],
                "enrollment": 194,
                "primary_outcomes": [
                  {
                    "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                    "description": "The levels of the study drug will be measured in whole blood",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                    "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                    "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                    "timeFrame": "Baseline to study end (approximately 12 months)"
                  }
                ],
                "primary_completion_date": "2028-07",
                "completion_date": "2028-07",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Age 65 to 90 years 2. Men and women 3. In good health with all medical problems stable. 4. Community-dwelling 5. Agreement to adhere to Lifestyle Considerations throughout study duration. 6. Ability of participant to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Resident of nursing home or long-term care f",
                "arms_count": 0,
                "has_results": false
              },
              {
                "nct_id": "NCT05836025",
                "brief_title": "Effect of Rapamycin in Ovarian Aging",
                "official_title": "Effect of Rapamycin in Ovarian Aging",
                "overall_status": "ACTIVE_NOT_RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "PHASE2"
                ],
                "enrollment": 50,
                "primary_outcomes": [
                  {
                    "measure": "Measure of Ovarian Reserve",
                    "description": "Ovarian reserve will be determined using AMH",
                    "timeFrame": "Up to 1 year"
                  }
                ],
                "primary_completion_date": "2025-10-21",
                "completion_date": "2026-09",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: * Women aged 35-45 years * In the menopausal transition stage -3a * Have been unable to conceive based on diminished ovarian reserve and who have failed to develop any euploid embryos with IVF or who do not desire to conceive within the next 1.5 years * Have regular menstrual periods (with less than 7 days of variability) * Early follicular phase follicle stimulating hormone (FSH) levels \\] \\< 20 mIU/mL * Anti-mllerian hormone (AMH) levels of \\>0.1 ng/mL * Antral Follicle Co",
                "arms_count": 0,
                "has_results": false
              },
              {
                "nct_id": "NCT07092618",
                "brief_title": "Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation",
                "official_title": "Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation: A Randomized, Controlled Trial",
                "overall_status": "RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "PHASE2",
                  "PHASE3"
                ],
                "enrollment": 150,
                "primary_outcomes": [
                  {
                    "measure": "Evaluate the effectiveness of metformin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic or Wegovy (or compounded semaglutide equivalent)",
                    "description": "Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline.\n\n1. Individuals that maintain the relative weight over the course of six months post-GLP-1 receptor agonist cessation\n2. Individuals that have less weight gain over the course of six months post-GLP-1 receptor agonist cessation using the combinatorial therapies than those who do not",
                    "timeFrame": "6 months"
                  },
                  {
                    "measure": "Evaluate the effectiveness of metformin + rapamycin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent)",
                    "description": "Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline.",
                    "timeFrame": "6 months"
                  },
                  {
                    "measure": "Evaluate the effectiveness of metformin + LDN in maintaining GLP1-induced weight loss in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent)",
                    "description": "Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline.",
                    "timeFrame": "6 months"
                  }
                ],
                "primary_completion_date": "2025-08",
                "completion_date": "2025-08",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: * Existing AgelessRx patient * Adults (40 - 85 years of age) * Any sex * Any ethnicity * BMI  22 kg/m\\^2 * Have been on GLP-1s (Wegovy, Ozempic, or a compounded form of GLP-1s) for at least three months before study initiation * Have lost at least 15 lbs during their GLP-1 use Exclusion Criteria: * Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s) * History of bari",
                "arms_count": 0,
                "has_results": false
              }
            ],
            "include_raw": false
          },
          "ids": [
            "NCT06658093",
            "NCT05836025",
            "NCT07092618"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "clinicaltrials_NCT06658093.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/clinicaltrials_fetch/manual-017/raw/clinicaltrials_NCT06658093.json",
              "sha256": "4482a1a06dd9fca7a81621f6c813247b3bb6469af4c723696e13547897c0b016",
              "size_bytes": 23444
            },
            {
              "kind": "raw_json",
              "name": "clinicaltrials_NCT05836025.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/clinicaltrials_fetch/manual-017/raw/clinicaltrials_NCT05836025.json",
              "sha256": "e76dbf4d6f924c8f2159db65c3c9e8eabc2ecde7d14d71f14bbafcb52c3b7d50",
              "size_bytes": 8450
            },
            {
              "kind": "raw_json",
              "name": "clinicaltrials_NCT07092618.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/clinicaltrials_fetch/manual-017/raw/clinicaltrials_NCT07092618.json",
              "sha256": "50fe1815fe8b09b1bb0b79730a21b8f4f0f6a44f519fbf89362ad7adf8a660a0",
              "size_bytes": 23188
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "clinicaltrials",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:11.539842Z",
            "data_schema_version": "v2.1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-017"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 765.85,
      "endpoint": "https://clinicaltrials.gov/api/v2/studies/{nct_id}",
      "enabled": true
    },
    {
      "tool": "trial_publication_linker",
      "payload": {
        "nct_ids": [
          "NCT06658093",
          "NCT05836025",
          "NCT07092618"
        ],
        "trials": [
          {
            "nct_id": "NCT06658093",
            "brief_title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
            "official_title": "RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects",
            "overall_status": "RECRUITING",
            "study_type": "INTERVENTIONAL",
            "phases": [
              "EARLY_PHASE1"
            ],
            "enrollment": 194,
            "primary_outcomes": [
              {
                "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                "description": "The levels of the study drug will be measured in whole blood",
                "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
              },
              {
                "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
              },
              {
                "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                "timeFrame": "Baseline to study end (approximately 12 months)"
              }
            ],
            "primary_completion_date": "2028-07",
            "completion_date": "2028-07",
            "results_first_posted_date": null,
            "eligibility_summary": "Inclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Age 65 to 90 years 2. Men and women 3. In good health with all medical problems stable. 4. Community-dwelling 5. Agreement to adhere to Lifestyle Considerations throughout study duration. 6. Ability of participant to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Resident of nursing home or long-term care f",
            "arms_count": 0,
            "has_results": false
          },
          {
            "nct_id": "NCT05836025",
            "brief_title": "Effect of Rapamycin in Ovarian Aging",
            "official_title": "Effect of Rapamycin in Ovarian Aging",
            "overall_status": "ACTIVE_NOT_RECRUITING",
            "study_type": "INTERVENTIONAL",
            "phases": [
              "PHASE2"
            ],
            "enrollment": 50,
            "primary_outcomes": [
              {
                "measure": "Measure of Ovarian Reserve",
                "description": "Ovarian reserve will be determined using AMH",
                "timeFrame": "Up to 1 year"
              }
            ],
            "primary_completion_date": "2025-10-21",
            "completion_date": "2026-09",
            "results_first_posted_date": null,
            "eligibility_summary": "Inclusion Criteria: * Women aged 35-45 years * In the menopausal transition stage -3a * Have been unable to conceive based on diminished ovarian reserve and who have failed to develop any euploid embryos with IVF or who do not desire to conceive within the next 1.5 years * Have regular menstrual periods (with less than 7 days of variability) * Early follicular phase follicle stimulating hormone (FSH) levels \\] \\< 20 mIU/mL * Anti-mllerian hormone (AMH) levels of \\>0.1 ng/mL * Antral Follicle Co",
            "arms_count": 0,
            "has_results": false
          },
          {
            "nct_id": "NCT07092618",
            "brief_title": "Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation",
            "official_title": "Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation: A Randomized, Controlled Trial",
            "overall_status": "RECRUITING",
            "study_type": "INTERVENTIONAL",
            "phases": [
              "PHASE2",
              "PHASE3"
            ],
            "enrollment": 150,
            "primary_outcomes": [
              {
                "measure": "Evaluate the effectiveness of metformin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic or Wegovy (or compounded semaglutide equivalent)",
                "description": "Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline.\n\n1. Individuals that maintain the relative weight over the course of six months post-GLP-1 receptor agonist cessation\n2. Individuals that have less weight gain over the course of six months post-GLP-1 receptor agonist cessation using the combinatorial therapies than those who do not",
                "timeFrame": "6 months"
              },
              {
                "measure": "Evaluate the effectiveness of metformin + rapamycin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent)",
                "description": "Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline.",
                "timeFrame": "6 months"
              },
              {
                "measure": "Evaluate the effectiveness of metformin + LDN in maintaining GLP1-induced weight loss in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent)",
                "description": "Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline.",
                "timeFrame": "6 months"
              }
            ],
            "primary_completion_date": "2025-08",
            "completion_date": "2025-08",
            "results_first_posted_date": null,
            "eligibility_summary": "Inclusion Criteria: * Existing AgelessRx patient * Adults (40 - 85 years of age) * Any sex * Any ethnicity * BMI  22 kg/m\\^2 * Have been on GLP-1s (Wegovy, Ozempic, or a compounded form of GLP-1s) for at least three months before study initiation * Have lost at least 15 lbs during their GLP-1 use Exclusion Criteria: * Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s) * History of bari",
            "arms_count": 0,
            "has_results": false
          }
        ]
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Linked 3 trial(s) to publication evidence.",
          "data": {
            "links": [
              {
                "nct_id": "NCT06658093",
                "status": "RECRUITING",
                "has_results": false,
                "completion_date": "2028-07",
                "pmids": [],
                "pubmed_match_mode": "none",
                "openalex_ids": [],
                "counts": {
                  "pmid_count": 0,
                  "openalex_count": 0
                },
                "flag": "no_mismatch_signal",
                "warnings": []
              },
              {
                "nct_id": "NCT05836025",
                "status": "ACTIVE_NOT_RECRUITING",
                "has_results": false,
                "completion_date": "2026-09",
                "pmids": [],
                "pubmed_match_mode": "none",
                "openalex_ids": [],
                "counts": {
                  "pmid_count": 0,
                  "openalex_count": 0
                },
                "flag": "no_mismatch_signal",
                "warnings": []
              },
              {
                "nct_id": "NCT07092618",
                "status": "RECRUITING",
                "has_results": false,
                "completion_date": "2025-08",
                "pmids": [],
                "pubmed_match_mode": "none",
                "openalex_ids": [],
                "counts": {
                  "pmid_count": 0,
                  "openalex_count": 0
                },
                "flag": "no_mismatch_signal",
                "warnings": []
              }
            ],
            "evidence_age_days": 365
          },
          "ids": [
            "NCT06658093",
            "NCT05836025",
            "NCT07092618"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "trial_publication_linker",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:14.334914Z",
            "data_schema_version": "v1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-018"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 2795.38,
      "endpoint": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi",
      "enabled": true
    },
    {
      "tool": "pubmed_fetch",
      "payload": {
        "ids": [
          "34567890",
          "31234567"
        ],
        "include_classification_fields": true
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Fetched 2 PubMed record(s).",
          "data": {
            "records": [
              {
                "pmid": "34567890",
                "title": "Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period.",
                "abstract": "Introduction With an estimated incidence of 2%-4% per year, the development of a second primary malignancy (SPM) in patients with head and neck tumors (HNTs) is not a rare event. The present study aimed to (i) assess the frequency of SPMs in patients with HNTs treated in a university hospital over a five-year period and (ii) provide a demographic characterization of these patients. Methods Retrospective single-centre study of patients with more than one primary tumor (including at least one HNT) diagnosed between January 1, 2015, and December 31, 2019. Data were retrieved from patients' clinical records and anonymized for analysis purposes. Results A total of 53 out of 824 (6.43%) patients with multiple primary malignancies were identified, 18 of which synchronous and 35 metachronous. The median follow-up was 25 months. Thirteen patients were diagnosed with more than one HNT. Forty patients were diagnosed with at least one HNT and one non-HNT. The most frequently diagnosed non-HNT SPMs were lung cancer (n=17) and esophageal cancer (n=8). The five-year survival rate was 53% for patients with multiple HNSCCs and 47% for patients with at least one non-HNT (log-rank p=0.729).The median overall survival was 14 months for synchronous and 58 months for metachronous SPMs (log-rank p=0.002). Conclusion Findings from this study highlight the importance of long-term follow-up of HNT patients for early detection of SPMs, increasing the chance of providing treatment with curative intent and improving patient outcomes and survival.",
                "publication_types": [
                  "Journal Article"
                ],
                "mesh_terms": [],
                "journal": "Cureus",
                "pub_date": "2021 Aug",
                "publication_year": 2021,
                "doi": "10.7759/cureus.17349",
                "nct_ids": [],
                "humans": false,
                "animals": false,
                "is_meta_or_systematic": false,
                "is_rct_like": false
              },
              {
                "pmid": "31234567",
                "title": "Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography.",
                "abstract": "This paper presents a method for the online determination of the spatial distribution of the moisture content in granular material. It might be essential for the monitoring and optimal control of, for example, drying processes. The proposed method utilizes Electrical Impedance Tomography (EIT). As an exemplary material for experimental research, the black chokeberry (Aronia melanocarpa) was used. The relationship between the electrical impedance of the chokeberry and its moisture content was determined for a wide range of frequencies (20 Hz-200 kHz). The EIT research consisted of both simulation and experimental investigation. Experimental studies of the spatial distribution of the moisture content were performed in a cylindrical vessel equipped with 8 electrodes circumferentially arranged. The voltage signal from the electrodes was acquired simultaneously using the data acquisition module. Due to the high impedance of the chokeberries, exceeding 109  for the dried matter, extraordinary instrumentation was necessary to be applied. On the other hand, raw chokeberry was characterized by a several orders of magnitude lower impedance (103-104 ), especially for high frequencies. The wide range of the observed impedance was able to be measured owing to its use of the voltage stimulation instead of the current stimulation (which is most common for EIT). The image reconstruction problem was solved using an iterative Gauss-Newton algorithm and the EIDORS (Electrical Impedance Tomography and Diffuse Optical Tomography Reconstruction Software) package. The obtained results showed a satisfactory ability to localize an insufficiently dried part of the material. Prospective ways to improve the imaging quality are also discussed.",
                "publication_types": [
                  "Journal Article"
                ],
                "mesh_terms": [],
                "journal": "Sensors (Basel, Switzerland)",
                "pub_date": "2019 Jun 23",
                "publication_year": 2019,
                "doi": "10.3390/s19122807",
                "nct_ids": [],
                "humans": false,
                "animals": false,
                "is_meta_or_systematic": false,
                "is_rct_like": false
              }
            ]
          },
          "ids": [
            "34567890",
            "31234567"
          ],
          "citations": [
            {
              "pmid": "34567890",
              "doi": "10.7759/cureus.17349",
              "title": "Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period.",
              "year": 2021
            },
            {
              "pmid": "31234567",
              "doi": "10.3390/s19122807",
              "title": "Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography.",
              "year": 2019
            }
          ],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "pubmed_fetch.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/pubmed_fetch/manual-019/raw/pubmed_fetch.json",
              "sha256": "e4cfa136a2abbfa3b368193403d4921938f126dd9bdf53fb2dcda5fcead0f246",
              "size_bytes": 26566
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "pubmed",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:15.015839Z",
            "data_schema_version": "v2.1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-019"
            }
          }
        }
      },
      "note": "best-effort classification sample",
      "latency_ms": 680.33,
      "endpoint": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi",
      "enabled": true
    },
    {
      "tool": "clinicaltrials_get_studies",
      "payload": {
        "nct_ids": [
          "NCT06658093",
          "NCT05836025"
        ]
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Fetched 2 ClinicalTrials.gov study detail record(s).",
          "data": {
            "studies": [
              {
                "nct_id": "NCT06658093",
                "brief_title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
                "official_title": "RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects",
                "overall_status": "RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "EARLY_PHASE1"
                ],
                "enrollment": 194,
                "primary_outcomes": [
                  {
                    "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                    "description": "The levels of the study drug will be measured in whole blood",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                    "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                    "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                    "timeFrame": "Baseline to study end (approximately 12 months)"
                  }
                ],
                "primary_completion_date": "2028-07",
                "completion_date": "2028-07",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Age 65 to 90 years 2. Men and women 3. In good health with all medical problems stable. 4. Community-dwelling 5. Agreement to adhere to Lifestyle Considerations throughout study duration. 6. Ability of participant to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Resident of nursing home or long-term care f",
                "arms_count": 0,
                "has_results": false
              },
              {
                "nct_id": "NCT05836025",
                "brief_title": "Effect of Rapamycin in Ovarian Aging",
                "official_title": "Effect of Rapamycin in Ovarian Aging",
                "overall_status": "ACTIVE_NOT_RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "PHASE2"
                ],
                "enrollment": 50,
                "primary_outcomes": [
                  {
                    "measure": "Measure of Ovarian Reserve",
                    "description": "Ovarian reserve will be determined using AMH",
                    "timeFrame": "Up to 1 year"
                  }
                ],
                "primary_completion_date": "2025-10-21",
                "completion_date": "2026-09",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: * Women aged 35-45 years * In the menopausal transition stage -3a * Have been unable to conceive based on diminished ovarian reserve and who have failed to develop any euploid embryos with IVF or who do not desire to conceive within the next 1.5 years * Have regular menstrual periods (with less than 7 days of variability) * Early follicular phase follicle stimulating hormone (FSH) levels \\] \\< 20 mIU/mL * Anti-mllerian hormone (AMH) levels of \\>0.1 ng/mL * Antral Follicle Co",
                "arms_count": 0,
                "has_results": false
              }
            ],
            "include_raw": false
          },
          "ids": [
            "NCT06658093",
            "NCT05836025"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "clinicaltrials_NCT06658093.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/clinicaltrials_get_studies/manual-020/raw/clinicaltrials_NCT06658093.json",
              "sha256": "4482a1a06dd9fca7a81621f6c813247b3bb6469af4c723696e13547897c0b016",
              "size_bytes": 23444
            },
            {
              "kind": "raw_json",
              "name": "clinicaltrials_NCT05836025.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/clinicaltrials_get_studies/manual-020/raw/clinicaltrials_NCT05836025.json",
              "sha256": "e76dbf4d6f924c8f2159db65c3c9e8eabc2ecde7d14d71f14bbafcb52c3b7d50",
              "size_bytes": 8450
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "clinicaltrials",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:15.434939Z",
            "data_schema_version": "v2.1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-020"
            }
          }
        }
      },
      "note": "classification sample",
      "latency_ms": 419.23,
      "endpoint": "https://clinicaltrials.gov/api/v2/studies/{nct_id}",
      "enabled": true
    },
    {
      "tool": "evidence_classify_pubmed_records",
      "payload": {
        "records": [
          {
            "pmid": "34567890",
            "title": "Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period.",
            "abstract": "Introduction With an estimated incidence of 2%-4% per year, the development of a second primary malignancy (SPM) in patients with head and neck tumors (HNTs) is not a rare event. The present study aimed to (i) assess the frequency of SPMs in patients with HNTs treated in a university hospital over a five-year period and (ii) provide a demographic characterization of these patients. Methods Retrospective single-centre study of patients with more than one primary tumor (including at least one HNT) diagnosed between January 1, 2015, and December 31, 2019. Data were retrieved from patients' clinical records and anonymized for analysis purposes. Results A total of 53 out of 824 (6.43%) patients with multiple primary malignancies were identified, 18 of which synchronous and 35 metachronous. The median follow-up was 25 months. Thirteen patients were diagnosed with more than one HNT. Forty patients were diagnosed with at least one HNT and one non-HNT. The most frequently diagnosed non-HNT SPMs were lung cancer (n=17) and esophageal cancer (n=8). The five-year survival rate was 53% for patients with multiple HNSCCs and 47% for patients with at least one non-HNT (log-rank p=0.729).The median overall survival was 14 months for synchronous and 58 months for metachronous SPMs (log-rank p=0.002). Conclusion Findings from this study highlight the importance of long-term follow-up of HNT patients for early detection of SPMs, increasing the chance of providing treatment with curative intent and improving patient outcomes and survival.",
            "publication_types": [
              "Journal Article"
            ],
            "mesh_terms": [],
            "journal": "Cureus",
            "pub_date": "2021 Aug",
            "publication_year": 2021,
            "doi": "10.7759/cureus.17349",
            "nct_ids": [],
            "humans": false,
            "animals": false,
            "is_meta_or_systematic": false,
            "is_rct_like": false
          },
          {
            "pmid": "31234567",
            "title": "Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography.",
            "abstract": "This paper presents a method for the online determination of the spatial distribution of the moisture content in granular material. It might be essential for the monitoring and optimal control of, for example, drying processes. The proposed method utilizes Electrical Impedance Tomography (EIT). As an exemplary material for experimental research, the black chokeberry (Aronia melanocarpa) was used. The relationship between the electrical impedance of the chokeberry and its moisture content was determined for a wide range of frequencies (20 Hz-200 kHz). The EIT research consisted of both simulation and experimental investigation. Experimental studies of the spatial distribution of the moisture content were performed in a cylindrical vessel equipped with 8 electrodes circumferentially arranged. The voltage signal from the electrodes was acquired simultaneously using the data acquisition module. Due to the high impedance of the chokeberries, exceeding 109  for the dried matter, extraordinary instrumentation was necessary to be applied. On the other hand, raw chokeberry was characterized by a several orders of magnitude lower impedance (103-104 ), especially for high frequencies. The wide range of the observed impedance was able to be measured owing to its use of the voltage stimulation instead of the current stimulation (which is most common for EIT). The image reconstruction problem was solved using an iterative Gauss-Newton algorithm and the EIDORS (Electrical Impedance Tomography and Diffuse Optical Tomography Reconstruction Software) package. The obtained results showed a satisfactory ability to localize an insufficiently dried part of the material. Prospective ways to improve the imaging quality are also discussed.",
            "publication_types": [
              "Journal Article"
            ],
            "mesh_terms": [],
            "journal": "Sensors (Basel, Switzerland)",
            "pub_date": "2019 Jun 23",
            "publication_year": 2019,
            "doi": "10.3390/s19122807",
            "nct_ids": [],
            "humans": false,
            "animals": false,
            "is_meta_or_systematic": false,
            "is_rct_like": false
          }
        ]
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Classified 2 PubMed record(s) into evidence tiers.",
          "data": {
            "records": [
              {
                "study_key": "pmid:34567890",
                "source": "pubmed",
                "ids": {
                  "pmid": "34567890",
                  "doi": "10.7759/cureus.17349"
                },
                "title": "Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period.",
                "year": 2021,
                "evidence_level": 3,
                "study_type": "observational",
                "population_class": "unknown",
                "endpoint_class": "mechanistic_only",
                "quality_flags": [
                  "observational_risk_confounding"
                ],
                "directness_flags": [
                  "indirect_endpoint"
                ],
                "effect_direction": "unknown",
                "citations": [
                  {
                    "pmid": "34567890",
                    "doi": "10.7759/cureus.17349",
                    "title": "Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period."
                  }
                ],
                "metadata": {
                  "pub_types": [
                    "Journal Article"
                  ],
                  "mesh_terms": [],
                  "hallmark_tags": []
                }
              },
              {
                "study_key": "pmid:31234567",
                "source": "pubmed",
                "ids": {
                  "pmid": "31234567",
                  "doi": "10.3390/s19122807"
                },
                "title": "Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography.",
                "year": 2019,
                "evidence_level": 6,
                "study_type": "in_silico",
                "population_class": "computational",
                "endpoint_class": "mechanistic_only",
                "quality_flags": [],
                "directness_flags": [
                  "indirect_endpoint"
                ],
                "effect_direction": "unknown",
                "citations": [
                  {
                    "pmid": "31234567",
                    "doi": "10.3390/s19122807",
                    "title": "Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography."
                  }
                ],
                "metadata": {
                  "pub_types": [
                    "Journal Article"
                  ],
                  "mesh_terms": [],
                  "hallmark_tags": []
                }
              }
            ]
          },
          "ids": [
            "pmid:34567890",
            "pmid:31234567"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "evidence",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:15.440056Z",
            "data_schema_version": "v2.1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-021"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 4.91,
      "endpoint": "internal",
      "enabled": true
    },
    {
      "tool": "evidence_classify_trial_records",
      "payload": {
        "records": [
          {
            "nct_id": "NCT06658093",
            "brief_title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
            "official_title": "RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects",
            "overall_status": "RECRUITING",
            "study_type": "INTERVENTIONAL",
            "phases": [
              "EARLY_PHASE1"
            ],
            "enrollment": 194,
            "primary_outcomes": [
              {
                "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                "description": "The levels of the study drug will be measured in whole blood",
                "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
              },
              {
                "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
              },
              {
                "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                "timeFrame": "Baseline to study end (approximately 12 months)"
              }
            ],
            "primary_completion_date": "2028-07",
            "completion_date": "2028-07",
            "results_first_posted_date": null,
            "eligibility_summary": "Inclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Age 65 to 90 years 2. Men and women 3. In good health with all medical problems stable. 4. Community-dwelling 5. Agreement to adhere to Lifestyle Considerations throughout study duration. 6. Ability of participant to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Resident of nursing home or long-term care f",
            "arms_count": 0,
            "has_results": false
          },
          {
            "nct_id": "NCT05836025",
            "brief_title": "Effect of Rapamycin in Ovarian Aging",
            "official_title": "Effect of Rapamycin in Ovarian Aging",
            "overall_status": "ACTIVE_NOT_RECRUITING",
            "study_type": "INTERVENTIONAL",
            "phases": [
              "PHASE2"
            ],
            "enrollment": 50,
            "primary_outcomes": [
              {
                "measure": "Measure of Ovarian Reserve",
                "description": "Ovarian reserve will be determined using AMH",
                "timeFrame": "Up to 1 year"
              }
            ],
            "primary_completion_date": "2025-10-21",
            "completion_date": "2026-09",
            "results_first_posted_date": null,
            "eligibility_summary": "Inclusion Criteria: * Women aged 35-45 years * In the menopausal transition stage -3a * Have been unable to conceive based on diminished ovarian reserve and who have failed to develop any euploid embryos with IVF or who do not desire to conceive within the next 1.5 years * Have regular menstrual periods (with less than 7 days of variability) * Early follicular phase follicle stimulating hormone (FSH) levels \\] \\< 20 mIU/mL * Anti-mllerian hormone (AMH) levels of \\>0.1 ng/mL * Antral Follicle Co",
            "arms_count": 0,
            "has_results": false
          }
        ]
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Classified 2 ClinicalTrials record(s).",
          "data": {
            "records": [
              {
                "study_key": "nct:NCT06658093",
                "source": "clinicaltrials",
                "ids": {
                  "nct": "NCT06658093"
                },
                "title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
                "year": 2028,
                "evidence_level": 2,
                "study_type": "registry_interventional",
                "population_class": "human_registry",
                "endpoint_class": "mechanistic_only",
                "quality_flags": [
                  "not_completed",
                  "no_registry_results"
                ],
                "directness_flags": [
                  "indirect_endpoint"
                ],
                "effect_direction": "unknown",
                "citations": [
                  {
                    "nct": "NCT06658093",
                    "title": "RESTOR: PK/PD mTORi Inhibition in Older Adults"
                  }
                ],
                "metadata": {
                  "overall_status": "RECRUITING",
                  "has_results": false,
                  "primary_completion_date": "2028-07",
                  "completion_date": "2028-07",
                  "results_first_posted_date": null,
                  "eligibility_summary": "Inclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Age 65 to 90 years 2. Men and women 3. In good health with all medical problems stable. 4. Community-dwelling 5. Agreement to adhere to Lifestyle Considerations throughout study duration. 6. Ability of participant to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Resident of nursing home or long-term care f",
                  "arms_count": 0,
                  "primary_outcomes": [
                    {
                      "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                      "description": "The levels of the study drug will be measured in whole blood",
                      "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                      "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                      "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                    },
                    {
                      "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                      "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    }
                  ],
                  "hallmark_tags": [
                    "nutrient_sensing"
                  ]
                }
              },
              {
                "study_key": "nct:NCT05836025",
                "source": "clinicaltrials",
                "ids": {
                  "nct": "NCT05836025"
                },
                "title": "Effect of Rapamycin in Ovarian Aging",
                "year": 2026,
                "evidence_level": 2,
                "study_type": "registry_interventional",
                "population_class": "human_registry",
                "endpoint_class": "mechanistic_only",
                "quality_flags": [
                  "not_completed",
                  "no_registry_results"
                ],
                "directness_flags": [
                  "indirect_endpoint"
                ],
                "effect_direction": "unknown",
                "citations": [
                  {
                    "nct": "NCT05836025",
                    "title": "Effect of Rapamycin in Ovarian Aging"
                  }
                ],
                "metadata": {
                  "overall_status": "ACTIVE_NOT_RECRUITING",
                  "has_results": false,
                  "primary_completion_date": "2025-10-21",
                  "completion_date": "2026-09",
                  "results_first_posted_date": null,
                  "eligibility_summary": "Inclusion Criteria: * Women aged 35-45 years * In the menopausal transition stage -3a * Have been unable to conceive based on diminished ovarian reserve and who have failed to develop any euploid embryos with IVF or who do not desire to conceive within the next 1.5 years * Have regular menstrual periods (with less than 7 days of variability) * Early follicular phase follicle stimulating hormone (FSH) levels \\] \\< 20 mIU/mL * Anti-mllerian hormone (AMH) levels of \\>0.1 ng/mL * Antral Follicle Co",
                  "arms_count": 0,
                  "primary_outcomes": [
                    {
                      "measure": "Measure of Ovarian Reserve",
                      "description": "Ovarian reserve will be determined using AMH",
                      "timeFrame": "Up to 1 year"
                    }
                  ],
                  "hallmark_tags": []
                }
              }
            ]
          },
          "ids": [
            "nct:NCT06658093",
            "nct:NCT05836025"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "evidence",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:15.441012Z",
            "data_schema_version": "v2.1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-022"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 0.93,
      "endpoint": "internal",
      "enabled": true
    },
    {
      "tool": "trial_publication_linker",
      "payload": {
        "nct_ids": [
          "NCT06658093",
          "NCT05836025"
        ],
        "trials": [
          {
            "nct_id": "NCT06658093",
            "brief_title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
            "official_title": "RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects",
            "overall_status": "RECRUITING",
            "study_type": "INTERVENTIONAL",
            "phases": [
              "EARLY_PHASE1"
            ],
            "enrollment": 194,
            "primary_outcomes": [
              {
                "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                "description": "The levels of the study drug will be measured in whole blood",
                "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
              },
              {
                "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
              },
              {
                "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                "timeFrame": "Baseline to study end (approximately 12 months)"
              }
            ],
            "primary_completion_date": "2028-07",
            "completion_date": "2028-07",
            "results_first_posted_date": null,
            "eligibility_summary": "Inclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Age 65 to 90 years 2. Men and women 3. In good health with all medical problems stable. 4. Community-dwelling 5. Agreement to adhere to Lifestyle Considerations throughout study duration. 6. Ability of participant to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Resident of nursing home or long-term care f",
            "arms_count": 0,
            "has_results": false
          },
          {
            "nct_id": "NCT05836025",
            "brief_title": "Effect of Rapamycin in Ovarian Aging",
            "official_title": "Effect of Rapamycin in Ovarian Aging",
            "overall_status": "ACTIVE_NOT_RECRUITING",
            "study_type": "INTERVENTIONAL",
            "phases": [
              "PHASE2"
            ],
            "enrollment": 50,
            "primary_outcomes": [
              {
                "measure": "Measure of Ovarian Reserve",
                "description": "Ovarian reserve will be determined using AMH",
                "timeFrame": "Up to 1 year"
              }
            ],
            "primary_completion_date": "2025-10-21",
            "completion_date": "2026-09",
            "results_first_posted_date": null,
            "eligibility_summary": "Inclusion Criteria: * Women aged 35-45 years * In the menopausal transition stage -3a * Have been unable to conceive based on diminished ovarian reserve and who have failed to develop any euploid embryos with IVF or who do not desire to conceive within the next 1.5 years * Have regular menstrual periods (with less than 7 days of variability) * Early follicular phase follicle stimulating hormone (FSH) levels \\] \\< 20 mIU/mL * Anti-mllerian hormone (AMH) levels of \\>0.1 ng/mL * Antral Follicle Co",
            "arms_count": 0,
            "has_results": false
          }
        ]
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Linked 2 trial(s) to publication evidence.",
          "data": {
            "links": [
              {
                "nct_id": "NCT06658093",
                "status": "RECRUITING",
                "has_results": false,
                "completion_date": "2028-07",
                "pmids": [],
                "pubmed_match_mode": "none",
                "openalex_ids": [],
                "counts": {
                  "pmid_count": 0,
                  "openalex_count": 0
                },
                "flag": "no_mismatch_signal",
                "warnings": []
              },
              {
                "nct_id": "NCT05836025",
                "status": "ACTIVE_NOT_RECRUITING",
                "has_results": false,
                "completion_date": "2026-09",
                "pmids": [],
                "pubmed_match_mode": "none",
                "openalex_ids": [],
                "counts": {
                  "pmid_count": 0,
                  "openalex_count": 0
                },
                "flag": "no_mismatch_signal",
                "warnings": []
              }
            ],
            "evidence_age_days": 365
          },
          "ids": [
            "NCT06658093",
            "NCT05836025"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "trial_publication_linker",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:20.134518Z",
            "data_schema_version": "v1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-023"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 4694.52,
      "endpoint": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi",
      "enabled": true
    },
    {
      "tool": "evidence_build_ledger",
      "payload": {
        "pubmed_records": [
          {
            "study_key": "pmid:34567890",
            "source": "pubmed",
            "ids": {
              "pmid": "34567890",
              "doi": "10.7759/cureus.17349"
            },
            "title": "Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period.",
            "year": 2021,
            "evidence_level": 3,
            "study_type": "observational",
            "population_class": "unknown",
            "endpoint_class": "mechanistic_only",
            "quality_flags": [
              "observational_risk_confounding"
            ],
            "directness_flags": [
              "indirect_endpoint"
            ],
            "effect_direction": "unknown",
            "citations": [
              {
                "pmid": "34567890",
                "doi": "10.7759/cureus.17349",
                "title": "Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period."
              }
            ],
            "metadata": {
              "pub_types": [
                "Journal Article"
              ],
              "mesh_terms": [],
              "hallmark_tags": []
            }
          },
          {
            "study_key": "pmid:31234567",
            "source": "pubmed",
            "ids": {
              "pmid": "31234567",
              "doi": "10.3390/s19122807"
            },
            "title": "Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography.",
            "year": 2019,
            "evidence_level": 6,
            "study_type": "in_silico",
            "population_class": "computational",
            "endpoint_class": "mechanistic_only",
            "quality_flags": [],
            "directness_flags": [
              "indirect_endpoint"
            ],
            "effect_direction": "unknown",
            "citations": [
              {
                "pmid": "31234567",
                "doi": "10.3390/s19122807",
                "title": "Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography."
              }
            ],
            "metadata": {
              "pub_types": [
                "Journal Article"
              ],
              "mesh_terms": [],
              "hallmark_tags": []
            }
          }
        ],
        "trial_records": [
          {
            "study_key": "nct:NCT06658093",
            "source": "clinicaltrials",
            "ids": {
              "nct": "NCT06658093"
            },
            "title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
            "year": 2028,
            "evidence_level": 2,
            "study_type": "registry_interventional",
            "population_class": "human_registry",
            "endpoint_class": "mechanistic_only",
            "quality_flags": [
              "not_completed",
              "no_registry_results"
            ],
            "directness_flags": [
              "indirect_endpoint"
            ],
            "effect_direction": "unknown",
            "citations": [
              {
                "nct": "NCT06658093",
                "title": "RESTOR: PK/PD mTORi Inhibition in Older Adults"
              }
            ],
            "metadata": {
              "overall_status": "RECRUITING",
              "has_results": false,
              "primary_completion_date": "2028-07",
              "completion_date": "2028-07",
              "results_first_posted_date": null,
              "eligibility_summary": "Inclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Age 65 to 90 years 2. Men and women 3. In good health with all medical problems stable. 4. Community-dwelling 5. Agreement to adhere to Lifestyle Considerations throughout study duration. 6. Ability of participant to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Resident of nursing home or long-term care f",
              "arms_count": 0,
              "primary_outcomes": [
                {
                  "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                  "description": "The levels of the study drug will be measured in whole blood",
                  "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                },
                {
                  "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                  "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                  "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                },
                {
                  "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                  "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                  "timeFrame": "Baseline to study end (approximately 12 months)"
                }
              ],
              "hallmark_tags": [
                "nutrient_sensing"
              ]
            }
          },
          {
            "study_key": "nct:NCT05836025",
            "source": "clinicaltrials",
            "ids": {
              "nct": "NCT05836025"
            },
            "title": "Effect of Rapamycin in Ovarian Aging",
            "year": 2026,
            "evidence_level": 2,
            "study_type": "registry_interventional",
            "population_class": "human_registry",
            "endpoint_class": "mechanistic_only",
            "quality_flags": [
              "not_completed",
              "no_registry_results"
            ],
            "directness_flags": [
              "indirect_endpoint"
            ],
            "effect_direction": "unknown",
            "citations": [
              {
                "nct": "NCT05836025",
                "title": "Effect of Rapamycin in Ovarian Aging"
              }
            ],
            "metadata": {
              "overall_status": "ACTIVE_NOT_RECRUITING",
              "has_results": false,
              "primary_completion_date": "2025-10-21",
              "completion_date": "2026-09",
              "results_first_posted_date": null,
              "eligibility_summary": "Inclusion Criteria: * Women aged 35-45 years * In the menopausal transition stage -3a * Have been unable to conceive based on diminished ovarian reserve and who have failed to develop any euploid embryos with IVF or who do not desire to conceive within the next 1.5 years * Have regular menstrual periods (with less than 7 days of variability) * Early follicular phase follicle stimulating hormone (FSH) levels \\] \\< 20 mIU/mL * Anti-mllerian hormone (AMH) levels of \\>0.1 ng/mL * Antral Follicle Co",
              "arms_count": 0,
              "primary_outcomes": [
                {
                  "measure": "Measure of Ovarian Reserve",
                  "description": "Ovarian reserve will be determined using AMH",
                  "timeFrame": "Up to 1 year"
                }
              ],
              "hallmark_tags": []
            }
          }
        ],
        "optional_source_status": [
          {
            "nct_id": "NCT06658093",
            "status": "RECRUITING",
            "has_results": false,
            "completion_date": "2028-07",
            "pmids": [],
            "pubmed_match_mode": "none",
            "openalex_ids": [],
            "counts": {
              "pmid_count": 0,
              "openalex_count": 0
            },
            "flag": "no_mismatch_signal",
            "warnings": []
          },
          {
            "nct_id": "NCT05836025",
            "status": "ACTIVE_NOT_RECRUITING",
            "has_results": false,
            "completion_date": "2026-09",
            "pmids": [],
            "pubmed_match_mode": "none",
            "openalex_ids": [],
            "counts": {
              "pmid_count": 0,
              "openalex_count": 0
            },
            "flag": "no_mismatch_signal",
            "warnings": []
          }
        ]
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Built evidence ledger with 4 unique record(s).",
          "data": {
            "records": [
              {
                "study_key": "pmid:34567890",
                "source": "pubmed",
                "title": "Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period.",
                "year": 2021,
                "ids": {
                  "pmid": "34567890",
                  "doi": "10.7759/cureus.17349"
                },
                "evidence_level": 3,
                "study_type": "observational",
                "population_class": "unknown",
                "endpoint_class": "mechanistic_only",
                "quality_flags": [
                  "observational_risk_confounding"
                ],
                "directness_flags": [
                  "indirect_endpoint"
                ],
                "effect_direction": "unknown",
                "citations": [
                  {
                    "pmid": "34567890",
                    "doi": "10.7759/cureus.17349",
                    "title": "Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period."
                  }
                ],
                "metadata": {
                  "pub_types": [
                    "Journal Article"
                  ],
                  "mesh_terms": [],
                  "hallmark_tags": []
                }
              },
              {
                "study_key": "pmid:31234567",
                "source": "pubmed",
                "title": "Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography.",
                "year": 2019,
                "ids": {
                  "pmid": "31234567",
                  "doi": "10.3390/s19122807"
                },
                "evidence_level": 6,
                "study_type": "in_silico",
                "population_class": "computational",
                "endpoint_class": "mechanistic_only",
                "quality_flags": [],
                "directness_flags": [
                  "indirect_endpoint"
                ],
                "effect_direction": "unknown",
                "citations": [
                  {
                    "pmid": "31234567",
                    "doi": "10.3390/s19122807",
                    "title": "Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography."
                  }
                ],
                "metadata": {
                  "pub_types": [
                    "Journal Article"
                  ],
                  "mesh_terms": [],
                  "hallmark_tags": []
                }
              },
              {
                "study_key": "nct:NCT06658093",
                "source": "clinicaltrials",
                "title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
                "year": 2028,
                "ids": {
                  "nct": "NCT06658093"
                },
                "evidence_level": 2,
                "study_type": "registry_interventional",
                "population_class": "human_registry",
                "endpoint_class": "mechanistic_only",
                "quality_flags": [
                  "not_completed",
                  "no_registry_results"
                ],
                "directness_flags": [
                  "indirect_endpoint"
                ],
                "effect_direction": "unknown",
                "citations": [
                  {
                    "nct": "NCT06658093",
                    "title": "RESTOR: PK/PD mTORi Inhibition in Older Adults"
                  }
                ],
                "metadata": {
                  "overall_status": "RECRUITING",
                  "has_results": false,
                  "primary_completion_date": "2028-07",
                  "completion_date": "2028-07",
                  "results_first_posted_date": null,
                  "eligibility_summary": "Inclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Age 65 to 90 years 2. Men and women 3. In good health with all medical problems stable. 4. Community-dwelling 5. Agreement to adhere to Lifestyle Considerations throughout study duration. 6. Ability of participant to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Resident of nursing home or long-term care f",
                  "arms_count": 0,
                  "primary_outcomes": [
                    {
                      "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                      "description": "The levels of the study drug will be measured in whole blood",
                      "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                      "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                      "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                    },
                    {
                      "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                      "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    }
                  ],
                  "hallmark_tags": [
                    "nutrient_sensing"
                  ]
                }
              },
              {
                "study_key": "nct:NCT05836025",
                "source": "clinicaltrials",
                "title": "Effect of Rapamycin in Ovarian Aging",
                "year": 2026,
                "ids": {
                  "nct": "NCT05836025"
                },
                "evidence_level": 2,
                "study_type": "registry_interventional",
                "population_class": "human_registry",
                "endpoint_class": "mechanistic_only",
                "quality_flags": [
                  "not_completed",
                  "no_registry_results"
                ],
                "directness_flags": [
                  "indirect_endpoint"
                ],
                "effect_direction": "unknown",
                "citations": [
                  {
                    "nct": "NCT05836025",
                    "title": "Effect of Rapamycin in Ovarian Aging"
                  }
                ],
                "metadata": {
                  "overall_status": "ACTIVE_NOT_RECRUITING",
                  "has_results": false,
                  "primary_completion_date": "2025-10-21",
                  "completion_date": "2026-09",
                  "results_first_posted_date": null,
                  "eligibility_summary": "Inclusion Criteria: * Women aged 35-45 years * In the menopausal transition stage -3a * Have been unable to conceive based on diminished ovarian reserve and who have failed to develop any euploid embryos with IVF or who do not desire to conceive within the next 1.5 years * Have regular menstrual periods (with less than 7 days of variability) * Early follicular phase follicle stimulating hormone (FSH) levels \\] \\< 20 mIU/mL * Anti-mllerian hormone (AMH) levels of \\>0.1 ng/mL * Antral Follicle Co",
                  "arms_count": 0,
                  "primary_outcomes": [
                    {
                      "measure": "Measure of Ovarian Reserve",
                      "description": "Ovarian reserve will be determined using AMH",
                      "timeFrame": "Up to 1 year"
                    }
                  ],
                  "hallmark_tags": []
                }
              }
            ],
            "dedupe_stats": {
              "input_records": 4,
              "unique_records": 4,
              "duplicates_removed": 0
            },
            "counts_by_level": {
              "3": 1,
              "6": 1,
              "2": 2
            },
            "counts_by_endpoint": {
              "mechanistic_only": 4
            },
            "counts_by_source": {
              "pubmed": 2,
              "clinicaltrials": 2
            },
            "coverage_gaps": [
              "No Level 1 evidence detected."
            ],
            "optional_source_status": [
              {
                "nct_id": "NCT06658093",
                "status": "RECRUITING",
                "has_results": false,
                "completion_date": "2028-07",
                "pmids": [],
                "pubmed_match_mode": "none",
                "openalex_ids": [],
                "counts": {
                  "pmid_count": 0,
                  "openalex_count": 0
                },
                "flag": "no_mismatch_signal",
                "warnings": []
              },
              {
                "nct_id": "NCT05836025",
                "status": "ACTIVE_NOT_RECRUITING",
                "has_results": false,
                "completion_date": "2026-09",
                "pmids": [],
                "pubmed_match_mode": "none",
                "openalex_ids": [],
                "counts": {
                  "pmid_count": 0,
                  "openalex_count": 0
                },
                "flag": "no_mismatch_signal",
                "warnings": []
              }
            ]
          },
          "ids": [
            "pmid:34567890",
            "pmid:31234567",
            "nct:NCT06658093",
            "nct:NCT05836025"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "evidence",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:20.138680Z",
            "data_schema_version": "v2.1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-024"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 4.04,
      "endpoint": "internal",
      "enabled": true
    },
    {
      "tool": "evidence_grade",
      "payload": {
        "ledger": {
          "records": [
            {
              "study_key": "pmid:34567890",
              "source": "pubmed",
              "title": "Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period.",
              "year": 2021,
              "ids": {
                "pmid": "34567890",
                "doi": "10.7759/cureus.17349"
              },
              "evidence_level": 3,
              "study_type": "observational",
              "population_class": "unknown",
              "endpoint_class": "mechanistic_only",
              "quality_flags": [
                "observational_risk_confounding"
              ],
              "directness_flags": [
                "indirect_endpoint"
              ],
              "effect_direction": "unknown",
              "citations": [
                {
                  "pmid": "34567890",
                  "doi": "10.7759/cureus.17349",
                  "title": "Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period."
                }
              ],
              "metadata": {
                "pub_types": [
                  "Journal Article"
                ],
                "mesh_terms": [],
                "hallmark_tags": []
              }
            },
            {
              "study_key": "pmid:31234567",
              "source": "pubmed",
              "title": "Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography.",
              "year": 2019,
              "ids": {
                "pmid": "31234567",
                "doi": "10.3390/s19122807"
              },
              "evidence_level": 6,
              "study_type": "in_silico",
              "population_class": "computational",
              "endpoint_class": "mechanistic_only",
              "quality_flags": [],
              "directness_flags": [
                "indirect_endpoint"
              ],
              "effect_direction": "unknown",
              "citations": [
                {
                  "pmid": "31234567",
                  "doi": "10.3390/s19122807",
                  "title": "Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography."
                }
              ],
              "metadata": {
                "pub_types": [
                  "Journal Article"
                ],
                "mesh_terms": [],
                "hallmark_tags": []
              }
            },
            {
              "study_key": "nct:NCT06658093",
              "source": "clinicaltrials",
              "title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
              "year": 2028,
              "ids": {
                "nct": "NCT06658093"
              },
              "evidence_level": 2,
              "study_type": "registry_interventional",
              "population_class": "human_registry",
              "endpoint_class": "mechanistic_only",
              "quality_flags": [
                "not_completed",
                "no_registry_results"
              ],
              "directness_flags": [
                "indirect_endpoint"
              ],
              "effect_direction": "unknown",
              "citations": [
                {
                  "nct": "NCT06658093",
                  "title": "RESTOR: PK/PD mTORi Inhibition in Older Adults"
                }
              ],
              "metadata": {
                "overall_status": "RECRUITING",
                "has_results": false,
                "primary_completion_date": "2028-07",
                "completion_date": "2028-07",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Age 65 to 90 years 2. Men and women 3. In good health with all medical problems stable. 4. Community-dwelling 5. Agreement to adhere to Lifestyle Considerations throughout study duration. 6. Ability of participant to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Resident of nursing home or long-term care f",
                "arms_count": 0,
                "primary_outcomes": [
                  {
                    "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                    "description": "The levels of the study drug will be measured in whole blood",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                    "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                    "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                    "timeFrame": "Baseline to study end (approximately 12 months)"
                  }
                ],
                "hallmark_tags": [
                  "nutrient_sensing"
                ]
              }
            },
            {
              "study_key": "nct:NCT05836025",
              "source": "clinicaltrials",
              "title": "Effect of Rapamycin in Ovarian Aging",
              "year": 2026,
              "ids": {
                "nct": "NCT05836025"
              },
              "evidence_level": 2,
              "study_type": "registry_interventional",
              "population_class": "human_registry",
              "endpoint_class": "mechanistic_only",
              "quality_flags": [
                "not_completed",
                "no_registry_results"
              ],
              "directness_flags": [
                "indirect_endpoint"
              ],
              "effect_direction": "unknown",
              "citations": [
                {
                  "nct": "NCT05836025",
                  "title": "Effect of Rapamycin in Ovarian Aging"
                }
              ],
              "metadata": {
                "overall_status": "ACTIVE_NOT_RECRUITING",
                "has_results": false,
                "primary_completion_date": "2025-10-21",
                "completion_date": "2026-09",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: * Women aged 35-45 years * In the menopausal transition stage -3a * Have been unable to conceive based on diminished ovarian reserve and who have failed to develop any euploid embryos with IVF or who do not desire to conceive within the next 1.5 years * Have regular menstrual periods (with less than 7 days of variability) * Early follicular phase follicle stimulating hormone (FSH) levels \\] \\< 20 mIU/mL * Anti-mllerian hormone (AMH) levels of \\>0.1 ng/mL * Antral Follicle Co",
                "arms_count": 0,
                "primary_outcomes": [
                  {
                    "measure": "Measure of Ovarian Reserve",
                    "description": "Ovarian reserve will be determined using AMH",
                    "timeFrame": "Up to 1 year"
                  }
                ],
                "hallmark_tags": []
              }
            }
          ],
          "dedupe_stats": {
            "input_records": 4,
            "unique_records": 4,
            "duplicates_removed": 0
          },
          "counts_by_level": {
            "3": 1,
            "6": 1,
            "2": 2
          },
          "counts_by_endpoint": {
            "mechanistic_only": 4
          },
          "counts_by_source": {
            "pubmed": 2,
            "clinicaltrials": 2
          },
          "coverage_gaps": [
            "No Level 1 evidence detected."
          ],
          "optional_source_status": [
            {
              "nct_id": "NCT06658093",
              "status": "RECRUITING",
              "has_results": false,
              "completion_date": "2028-07",
              "pmids": [],
              "pubmed_match_mode": "none",
              "openalex_ids": [],
              "counts": {
                "pmid_count": 0,
                "openalex_count": 0
              },
              "flag": "no_mismatch_signal",
              "warnings": []
            },
            {
              "nct_id": "NCT05836025",
              "status": "ACTIVE_NOT_RECRUITING",
              "has_results": false,
              "completion_date": "2026-09",
              "pmids": [],
              "pubmed_match_mode": "none",
              "openalex_ids": [],
              "counts": {
                "pmid_count": 0,
                "openalex_count": 0
              },
              "flag": "no_mismatch_signal",
              "warnings": []
            }
          ]
        }
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Graded evidence ledger: 39.5 (E).",
          "data": {
            "score": 39.5,
            "label": "E",
            "confidence": "very_low",
            "trace": {
              "ces": 35.5,
              "mp": 10.0,
              "final_confidence": 39.5,
              "penalties": [
                {
                  "kind": "quality",
                  "flag": "observational_risk_confounding",
                  "count": 1,
                  "delta": -1.5
                },
                {
                  "kind": "quality",
                  "flag": "not_completed",
                  "count": 2,
                  "delta": -4.0
                },
                {
                  "kind": "quality",
                  "flag": "no_registry_results",
                  "count": 2,
                  "delta": -3.0
                }
              ],
              "bonuses": [
                {
                  "kind": "consistency",
                  "reason": "multiple_level2",
                  "delta": 2.5
                }
              ],
              "caps_applied": [],
              "components": {
                "level_counts": {
                  "2": 2,
                  "3": 1,
                  "6": 1
                },
                "ces_components": {
                  "level_2": 23.8,
                  "level_3": 10.4,
                  "level_6": 1.3
                },
                "endpoint_counts": {
                  "mechanistic_only": 4
                },
                "quality_flags": {
                  "observational_risk_confounding": 1,
                  "not_completed": 2,
                  "no_registry_results": 2
                },
                "hallmark_tag_count": 1,
                "human_count": 2,
                "quality_penalty": 8.5,
                "consistency_bonus": 2.5
              }
            },
            "notes": [
              "No hard clinical endpoints detected."
            ]
          },
          "ids": [
            "39.5"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "evidence",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:20.141656Z",
            "data_schema_version": "v2.1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-025"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 2.27,
      "endpoint": "internal",
      "enabled": true
    },
    {
      "tool": "evidence_gap_map",
      "payload": {
        "ledger": {
          "records": [
            {
              "study_key": "pmid:34567890",
              "source": "pubmed",
              "title": "Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period.",
              "year": 2021,
              "ids": {
                "pmid": "34567890",
                "doi": "10.7759/cureus.17349"
              },
              "evidence_level": 3,
              "study_type": "observational",
              "population_class": "unknown",
              "endpoint_class": "mechanistic_only",
              "quality_flags": [
                "observational_risk_confounding"
              ],
              "directness_flags": [
                "indirect_endpoint"
              ],
              "effect_direction": "unknown",
              "citations": [
                {
                  "pmid": "34567890",
                  "doi": "10.7759/cureus.17349",
                  "title": "Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period."
                }
              ],
              "metadata": {
                "pub_types": [
                  "Journal Article"
                ],
                "mesh_terms": [],
                "hallmark_tags": []
              }
            },
            {
              "study_key": "pmid:31234567",
              "source": "pubmed",
              "title": "Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography.",
              "year": 2019,
              "ids": {
                "pmid": "31234567",
                "doi": "10.3390/s19122807"
              },
              "evidence_level": 6,
              "study_type": "in_silico",
              "population_class": "computational",
              "endpoint_class": "mechanistic_only",
              "quality_flags": [],
              "directness_flags": [
                "indirect_endpoint"
              ],
              "effect_direction": "unknown",
              "citations": [
                {
                  "pmid": "31234567",
                  "doi": "10.3390/s19122807",
                  "title": "Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography."
                }
              ],
              "metadata": {
                "pub_types": [
                  "Journal Article"
                ],
                "mesh_terms": [],
                "hallmark_tags": []
              }
            },
            {
              "study_key": "nct:NCT06658093",
              "source": "clinicaltrials",
              "title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
              "year": 2028,
              "ids": {
                "nct": "NCT06658093"
              },
              "evidence_level": 2,
              "study_type": "registry_interventional",
              "population_class": "human_registry",
              "endpoint_class": "mechanistic_only",
              "quality_flags": [
                "not_completed",
                "no_registry_results"
              ],
              "directness_flags": [
                "indirect_endpoint"
              ],
              "effect_direction": "unknown",
              "citations": [
                {
                  "nct": "NCT06658093",
                  "title": "RESTOR: PK/PD mTORi Inhibition in Older Adults"
                }
              ],
              "metadata": {
                "overall_status": "RECRUITING",
                "has_results": false,
                "primary_completion_date": "2028-07",
                "completion_date": "2028-07",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Age 65 to 90 years 2. Men and women 3. In good health with all medical problems stable. 4. Community-dwelling 5. Agreement to adhere to Lifestyle Considerations throughout study duration. 6. Ability of participant to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Resident of nursing home or long-term care f",
                "arms_count": 0,
                "primary_outcomes": [
                  {
                    "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                    "description": "The levels of the study drug will be measured in whole blood",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                    "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                    "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                    "timeFrame": "Baseline to study end (approximately 12 months)"
                  }
                ],
                "hallmark_tags": [
                  "nutrient_sensing"
                ]
              }
            },
            {
              "study_key": "nct:NCT05836025",
              "source": "clinicaltrials",
              "title": "Effect of Rapamycin in Ovarian Aging",
              "year": 2026,
              "ids": {
                "nct": "NCT05836025"
              },
              "evidence_level": 2,
              "study_type": "registry_interventional",
              "population_class": "human_registry",
              "endpoint_class": "mechanistic_only",
              "quality_flags": [
                "not_completed",
                "no_registry_results"
              ],
              "directness_flags": [
                "indirect_endpoint"
              ],
              "effect_direction": "unknown",
              "citations": [
                {
                  "nct": "NCT05836025",
                  "title": "Effect of Rapamycin in Ovarian Aging"
                }
              ],
              "metadata": {
                "overall_status": "ACTIVE_NOT_RECRUITING",
                "has_results": false,
                "primary_completion_date": "2025-10-21",
                "completion_date": "2026-09",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: * Women aged 35-45 years * In the menopausal transition stage -3a * Have been unable to conceive based on diminished ovarian reserve and who have failed to develop any euploid embryos with IVF or who do not desire to conceive within the next 1.5 years * Have regular menstrual periods (with less than 7 days of variability) * Early follicular phase follicle stimulating hormone (FSH) levels \\] \\< 20 mIU/mL * Anti-mllerian hormone (AMH) levels of \\>0.1 ng/mL * Antral Follicle Co",
                "arms_count": 0,
                "primary_outcomes": [
                  {
                    "measure": "Measure of Ovarian Reserve",
                    "description": "Ovarian reserve will be determined using AMH",
                    "timeFrame": "Up to 1 year"
                  }
                ],
                "hallmark_tags": []
              }
            }
          ],
          "dedupe_stats": {
            "input_records": 4,
            "unique_records": 4,
            "duplicates_removed": 0
          },
          "counts_by_level": {
            "3": 1,
            "6": 1,
            "2": 2
          },
          "counts_by_endpoint": {
            "mechanistic_only": 4
          },
          "counts_by_source": {
            "pubmed": 2,
            "clinicaltrials": 2
          },
          "coverage_gaps": [
            "No Level 1 evidence detected."
          ],
          "optional_source_status": [
            {
              "nct_id": "NCT06658093",
              "status": "RECRUITING",
              "has_results": false,
              "completion_date": "2028-07",
              "pmids": [],
              "pubmed_match_mode": "none",
              "openalex_ids": [],
              "counts": {
                "pmid_count": 0,
                "openalex_count": 0
              },
              "flag": "no_mismatch_signal",
              "warnings": []
            },
            {
              "nct_id": "NCT05836025",
              "status": "ACTIVE_NOT_RECRUITING",
              "has_results": false,
              "completion_date": "2026-09",
              "pmids": [],
              "pubmed_match_mode": "none",
              "openalex_ids": [],
              "counts": {
                "pmid_count": 0,
                "openalex_count": 0
              },
              "flag": "no_mismatch_signal",
              "warnings": []
            }
          ]
        },
        "grade": {
          "score": 39.5,
          "label": "E",
          "confidence": "very_low",
          "trace": {
            "ces": 35.5,
            "mp": 10.0,
            "final_confidence": 39.5,
            "penalties": [
              {
                "kind": "quality",
                "flag": "observational_risk_confounding",
                "count": 1,
                "delta": -1.5
              },
              {
                "kind": "quality",
                "flag": "not_completed",
                "count": 2,
                "delta": -4.0
              },
              {
                "kind": "quality",
                "flag": "no_registry_results",
                "count": 2,
                "delta": -3.0
              }
            ],
            "bonuses": [
              {
                "kind": "consistency",
                "reason": "multiple_level2",
                "delta": 2.5
              }
            ],
            "caps_applied": [],
            "components": {
              "level_counts": {
                "2": 2,
                "3": 1,
                "6": 1
              },
              "ces_components": {
                "level_2": 23.8,
                "level_3": 10.4,
                "level_6": 1.3
              },
              "endpoint_counts": {
                "mechanistic_only": 4
              },
              "quality_flags": {
                "observational_risk_confounding": 1,
                "not_completed": 2,
                "no_registry_results": 2
              },
              "hallmark_tag_count": 1,
              "human_count": 2,
              "quality_penalty": 8.5,
              "consistency_bonus": 2.5
            }
          },
          "notes": [
            "No hard clinical endpoints detected."
          ]
        }
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Computed evidence gap map.",
          "data": {
            "missing_levels": [
              "No systematic review or meta-analysis evidence (Level 1)."
            ],
            "missing_endpoints": [
              "No hard clinical endpoints identified."
            ],
            "next_best_studies": [
              "Add hard endpoint follow-up (e.g., morbidity, hospitalization, or validated functional decline endpoints)."
            ],
            "mismatch_cautions": [],
            "level_counts": {
              "2": 2,
              "3": 1,
              "6": 1
            },
            "endpoint_counts": {
              "mechanistic_only": 4
            }
          },
          "ids": [
            "No systematic review or meta-analysis evidence (Level 1)."
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "evidence",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:20.143562Z",
            "data_schema_version": "v2.1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-026"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 1.61,
      "endpoint": "internal",
      "enabled": true
    },
    {
      "tool": "evidence_render_report",
      "payload": {
        "intervention": {
          "label": "sirolimus",
          "type": "drug",
          "pivot": {
            "source": "rxnorm",
            "id": "35302"
          },
          "synonyms": [
            {
              "text": "1094-61-7",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "nicotinamide mononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Nicotinamide ribotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "2KG6QX4W0V",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "DTXSID50911152",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Alpha9",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "3-carbamoyl-1-((2R,3R,4S,5R)-5-((hydrogen phosphonatooxy)methyl)-3,4-dihydroxyoxolan-2-yl)-1$l^(5)-pyridin-1-ylium",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "ELITEHEALTH",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "REUS NR",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "RefChem:854107",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Mononucleotide, Nicotinamide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "CHEBI:50383",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "DTXCID001511294",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "214-136-5",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "3-carboxy-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-((phosphonooxy)methyl)oxolan-2-yl)-1lambda5-pyridin-1-ylium",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "beta-Nicotinamide mononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "beta-NMN",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "NMN zwitterion",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "NMN",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "nicotinamide nucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "nicotinamide ribonucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "beta-nicotinamide D-ribonucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "nicotinamide D-ribonucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "BETANMN",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "beta-Nicotinamide ribonucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "MFCD00038748",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "3-(Aminocarbonyl)-1-(5-O-phosphonato-beta-D-ribofuranosyl)pyridinium",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "B-NICOTINAMIDE MONONUCLEOTIDE",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Nicotinamide ribonucleoside 5'-phosphate",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "beta-nicotinamide ribose monophosphate",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "b-D-NMN",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "C11H15N2O8P",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "BETA-D-NMN",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "UNII-2KG6QX4W0V",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "reinvigorator",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Fosribnicotinamide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "EINECS 214-136-5",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "ss-NMN",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Nicotine Impurity 9",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Nicotinamidmononucleotid",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "fosribnicotinamide [INN]",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "-NM;NMN",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "bmse000260",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "-Nicotinamide mononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "?-Nicotinamidemononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "Nicotinamide Mononucleotide?",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "NMN [MI]",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "|A-Nicotinamidemononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "?-Nicotinamide Mononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "ss-Nicotinamide mononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "fA-Nicotinamide Mononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "SCHEMBL105618",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "|_-Nicotinamide Mononucleotide",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "CHEMBL610238",
              "source": "pubchem",
              "weight": 0.7
            },
            {
              "text": "orb1302620",
              "source": "pubchem",
              "weight": 0.7
            }
          ],
          "xrefs": [
            {
              "source": "rxnorm",
              "id": "RxCUI:35302"
            }
          ],
          "warnings": []
        },
        "ledger": {
          "records": [
            {
              "study_key": "pmid:34567890",
              "source": "pubmed",
              "title": "Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period.",
              "year": 2021,
              "ids": {
                "pmid": "34567890",
                "doi": "10.7759/cureus.17349"
              },
              "evidence_level": 3,
              "study_type": "observational",
              "population_class": "unknown",
              "endpoint_class": "mechanistic_only",
              "quality_flags": [
                "observational_risk_confounding"
              ],
              "directness_flags": [
                "indirect_endpoint"
              ],
              "effect_direction": "unknown",
              "citations": [
                {
                  "pmid": "34567890",
                  "doi": "10.7759/cureus.17349",
                  "title": "Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period."
                }
              ],
              "metadata": {
                "pub_types": [
                  "Journal Article"
                ],
                "mesh_terms": [],
                "hallmark_tags": []
              }
            },
            {
              "study_key": "pmid:31234567",
              "source": "pubmed",
              "title": "Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography.",
              "year": 2019,
              "ids": {
                "pmid": "31234567",
                "doi": "10.3390/s19122807"
              },
              "evidence_level": 6,
              "study_type": "in_silico",
              "population_class": "computational",
              "endpoint_class": "mechanistic_only",
              "quality_flags": [],
              "directness_flags": [
                "indirect_endpoint"
              ],
              "effect_direction": "unknown",
              "citations": [
                {
                  "pmid": "31234567",
                  "doi": "10.3390/s19122807",
                  "title": "Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography."
                }
              ],
              "metadata": {
                "pub_types": [
                  "Journal Article"
                ],
                "mesh_terms": [],
                "hallmark_tags": []
              }
            },
            {
              "study_key": "nct:NCT06658093",
              "source": "clinicaltrials",
              "title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
              "year": 2028,
              "ids": {
                "nct": "NCT06658093"
              },
              "evidence_level": 2,
              "study_type": "registry_interventional",
              "population_class": "human_registry",
              "endpoint_class": "mechanistic_only",
              "quality_flags": [
                "not_completed",
                "no_registry_results"
              ],
              "directness_flags": [
                "indirect_endpoint"
              ],
              "effect_direction": "unknown",
              "citations": [
                {
                  "nct": "NCT06658093",
                  "title": "RESTOR: PK/PD mTORi Inhibition in Older Adults"
                }
              ],
              "metadata": {
                "overall_status": "RECRUITING",
                "has_results": false,
                "primary_completion_date": "2028-07",
                "completion_date": "2028-07",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Age 65 to 90 years 2. Men and women 3. In good health with all medical problems stable. 4. Community-dwelling 5. Agreement to adhere to Lifestyle Considerations throughout study duration. 6. Ability of participant to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Older Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2): 1. Resident of nursing home or long-term care f",
                "arms_count": 0,
                "primary_outcomes": [
                  {
                    "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                    "description": "The levels of the study drug will be measured in whole blood",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                    "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                    "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                    "timeFrame": "Baseline to study end (approximately 12 months)"
                  }
                ],
                "hallmark_tags": [
                  "nutrient_sensing"
                ]
              }
            },
            {
              "study_key": "nct:NCT05836025",
              "source": "clinicaltrials",
              "title": "Effect of Rapamycin in Ovarian Aging",
              "year": 2026,
              "ids": {
                "nct": "NCT05836025"
              },
              "evidence_level": 2,
              "study_type": "registry_interventional",
              "population_class": "human_registry",
              "endpoint_class": "mechanistic_only",
              "quality_flags": [
                "not_completed",
                "no_registry_results"
              ],
              "directness_flags": [
                "indirect_endpoint"
              ],
              "effect_direction": "unknown",
              "citations": [
                {
                  "nct": "NCT05836025",
                  "title": "Effect of Rapamycin in Ovarian Aging"
                }
              ],
              "metadata": {
                "overall_status": "ACTIVE_NOT_RECRUITING",
                "has_results": false,
                "primary_completion_date": "2025-10-21",
                "completion_date": "2026-09",
                "results_first_posted_date": null,
                "eligibility_summary": "Inclusion Criteria: * Women aged 35-45 years * In the menopausal transition stage -3a * Have been unable to conceive based on diminished ovarian reserve and who have failed to develop any euploid embryos with IVF or who do not desire to conceive within the next 1.5 years * Have regular menstrual periods (with less than 7 days of variability) * Early follicular phase follicle stimulating hormone (FSH) levels \\] \\< 20 mIU/mL * Anti-mllerian hormone (AMH) levels of \\>0.1 ng/mL * Antral Follicle Co",
                "arms_count": 0,
                "primary_outcomes": [
                  {
                    "measure": "Measure of Ovarian Reserve",
                    "description": "Ovarian reserve will be determined using AMH",
                    "timeFrame": "Up to 1 year"
                  }
                ],
                "hallmark_tags": []
              }
            }
          ],
          "dedupe_stats": {
            "input_records": 4,
            "unique_records": 4,
            "duplicates_removed": 0
          },
          "counts_by_level": {
            "3": 1,
            "6": 1,
            "2": 2
          },
          "counts_by_endpoint": {
            "mechanistic_only": 4
          },
          "counts_by_source": {
            "pubmed": 2,
            "clinicaltrials": 2
          },
          "coverage_gaps": [
            "No Level 1 evidence detected."
          ],
          "optional_source_status": [
            {
              "nct_id": "NCT06658093",
              "status": "RECRUITING",
              "has_results": false,
              "completion_date": "2028-07",
              "pmids": [],
              "pubmed_match_mode": "none",
              "openalex_ids": [],
              "counts": {
                "pmid_count": 0,
                "openalex_count": 0
              },
              "flag": "no_mismatch_signal",
              "warnings": []
            },
            {
              "nct_id": "NCT05836025",
              "status": "ACTIVE_NOT_RECRUITING",
              "has_results": false,
              "completion_date": "2026-09",
              "pmids": [],
              "pubmed_match_mode": "none",
              "openalex_ids": [],
              "counts": {
                "pmid_count": 0,
                "openalex_count": 0
              },
              "flag": "no_mismatch_signal",
              "warnings": []
            }
          ]
        },
        "grade": {
          "score": 39.5,
          "label": "E",
          "confidence": "very_low",
          "trace": {
            "ces": 35.5,
            "mp": 10.0,
            "final_confidence": 39.5,
            "penalties": [
              {
                "kind": "quality",
                "flag": "observational_risk_confounding",
                "count": 1,
                "delta": -1.5
              },
              {
                "kind": "quality",
                "flag": "not_completed",
                "count": 2,
                "delta": -4.0
              },
              {
                "kind": "quality",
                "flag": "no_registry_results",
                "count": 2,
                "delta": -3.0
              }
            ],
            "bonuses": [
              {
                "kind": "consistency",
                "reason": "multiple_level2",
                "delta": 2.5
              }
            ],
            "caps_applied": [],
            "components": {
              "level_counts": {
                "2": 2,
                "3": 1,
                "6": 1
              },
              "ces_components": {
                "level_2": 23.8,
                "level_3": 10.4,
                "level_6": 1.3
              },
              "endpoint_counts": {
                "mechanistic_only": 4
              },
              "quality_flags": {
                "observational_risk_confounding": 1,
                "not_completed": 2,
                "no_registry_results": 2
              },
              "hallmark_tag_count": 1,
              "human_count": 2,
              "quality_penalty": 8.5,
              "consistency_bonus": 2.5
            }
          },
          "notes": [
            "No hard clinical endpoints detected."
          ]
        },
        "gap_map": {
          "missing_levels": [
            "No systematic review or meta-analysis evidence (Level 1)."
          ],
          "missing_endpoints": [
            "No hard clinical endpoints identified."
          ],
          "next_best_studies": [
            "Add hard endpoint follow-up (e.g., morbidity, hospitalization, or validated functional decline endpoints)."
          ],
          "mismatch_cautions": [],
          "level_counts": {
            "2": 2,
            "3": 1,
            "6": 1
          },
          "endpoint_counts": {
            "mechanistic_only": 4
          }
        }
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Rendered evidence report markdown and JSON payload.",
          "data": {
            "report_markdown": "# Evidence Report: sirolimus\n\n- Type: drug\n- Pivot: {'source': 'rxnorm', 'id': '35302'}\n- Confidence score: 39.5 (E, very_low)\n\n## Evidence Pyramid\n- Level 1 (systematic/meta): 0\n- Level 2 (RCT): 2\n- Level 3 (observational): 1\n- Level 4 (animal): 0\n- Level 5 (in vitro): 0\n- Level 6 (in silico): 1\n\n## Main Gaps\n- No systematic review or meta-analysis evidence (Level 1).\n- No hard clinical endpoints identified.\n\n## What Would Raise Confidence\n- Add hard endpoint follow-up (e.g., morbidity, hospitalization, or validated functional decline endpoints).\n\n## Notes\n- No hard clinical endpoints detected.\n- No hard clinical endpoints detected.\n",
            "report_json": {
              "intervention": {
                "label": "sirolimus",
                "type": "drug",
                "pivot": {
                  "source": "rxnorm",
                  "id": "35302"
                },
                "synonyms": [
                  {
                    "text": "1094-61-7",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "nicotinamide mononucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Nicotinamide ribotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "2KG6QX4W0V",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "DTXSID50911152",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Alpha9",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "3-carbamoyl-1-((2R,3R,4S,5R)-5-((hydrogen phosphonatooxy)methyl)-3,4-dihydroxyoxolan-2-yl)-1$l^(5)-pyridin-1-ylium",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "ELITEHEALTH",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "REUS NR",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "RefChem:854107",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Mononucleotide, Nicotinamide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "CHEBI:50383",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "DTXCID001511294",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "214-136-5",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "3-carboxy-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-((phosphonooxy)methyl)oxolan-2-yl)-1lambda5-pyridin-1-ylium",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-Nicotinamide mononucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-NMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "NMN zwitterion",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "NMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "nicotinamide nucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "nicotinamide ribonucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-nicotinamide D-ribonucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "nicotinamide D-ribonucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "BETANMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-Nicotinamide ribonucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "MFCD00038748",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "3-(Aminocarbonyl)-1-(5-O-phosphonato-beta-D-ribofuranosyl)pyridinium",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "B-NICOTINAMIDE MONONUCLEOTIDE",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Nicotinamide ribonucleoside 5'-phosphate",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-nicotinamide ribose monophosphate",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "b-D-NMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "C11H15N2O8P",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "BETA-D-NMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "UNII-2KG6QX4W0V",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "reinvigorator",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Fosribnicotinamide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "EINECS 214-136-5",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "ss-NMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Nicotine Impurity 9",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Nicotinamidmononucleotid",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "fosribnicotinamide [INN]",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "-NM;NMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "bmse000260",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "-Nicotinamide mononucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "?-Nicotinamidemononucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Nicotinamide Mononucleotide?",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "NMN [MI]",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "|A-Nicotinamidemononucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "?-Nicotinamide Mononucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "ss-Nicotinamide mononucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "fA-Nicotinamide Mononucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "SCHEMBL105618",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "|_-Nicotinamide Mononucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "CHEMBL610238",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "orb1302620",
                    "source": "pubchem",
                    "weight": 0.7
                  }
                ],
                "xrefs": [
                  {
                    "source": "rxnorm",
                    "id": "RxCUI:35302"
                  }
                ],
                "warnings": []
              },
              "claim_context": null,
              "evidence_summary": {
                "score": 39.5,
                "label": "E",
                "confidence": "very_low",
                "notes": [
                  "No hard clinical endpoints detected.",
                  "No hard clinical endpoints detected."
                ]
              },
              "evidence_pyramid": {
                "level_1": 0,
                "level_2": 2,
                "level_3": 1,
                "level_4": 0,
                "level_5": 0,
                "level_6": 1
              },
              "counts_by_source": {
                "pubmed": 2,
                "clinicaltrials": 2
              },
              "counts_by_endpoint": {
                "mechanistic_only": 4
              },
              "scoring_trace": {
                "ces": 35.5,
                "mp": 10.0,
                "final_confidence": 39.5,
                "penalties": [
                  {
                    "kind": "quality",
                    "flag": "observational_risk_confounding",
                    "count": 1,
                    "delta": -1.5
                  },
                  {
                    "kind": "quality",
                    "flag": "not_completed",
                    "count": 2,
                    "delta": -4.0
                  },
                  {
                    "kind": "quality",
                    "flag": "no_registry_results",
                    "count": 2,
                    "delta": -3.0
                  }
                ],
                "bonuses": [
                  {
                    "kind": "consistency",
                    "reason": "multiple_level2",
                    "delta": 2.5
                  }
                ],
                "caps_applied": [],
                "components": {
                  "level_counts": {
                    "2": 2,
                    "3": 1,
                    "6": 1
                  },
                  "ces_components": {
                    "level_2": 23.8,
                    "level_3": 10.4,
                    "level_6": 1.3
                  },
                  "endpoint_counts": {
                    "mechanistic_only": 4
                  },
                  "quality_flags": {
                    "observational_risk_confounding": 1,
                    "not_completed": 2,
                    "no_registry_results": 2
                  },
                  "hallmark_tag_count": 1,
                  "human_count": 2,
                  "quality_penalty": 8.5,
                  "consistency_bonus": 2.5
                }
              },
              "coverage_gaps": [
                "No Level 1 evidence detected."
              ],
              "gap_map": {
                "missing_levels": [
                  "No systematic review or meta-analysis evidence (Level 1)."
                ],
                "missing_endpoints": [
                  "No hard clinical endpoints identified."
                ],
                "next_best_studies": [
                  "Add hard endpoint follow-up (e.g., morbidity, hospitalization, or validated functional decline endpoints)."
                ],
                "mismatch_cautions": [],
                "level_counts": {
                  "2": 2,
                  "3": 1,
                  "6": 1
                },
                "endpoint_counts": {
                  "mechanistic_only": 4
                }
              },
              "records": [
                {
                  "study_key": "pmid:34567890",
                  "source": "pubmed",
                  "title": "Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period.",
                  "year": 2021,
                  "evidence_level": 3,
                  "study_type": "observational",
                  "population_class": "unknown",
                  "endpoint_class": "mechanistic_only",
                  "effect_direction": "unknown",
                  "quality_flags": [
                    "observational_risk_confounding"
                  ],
                  "directness_flags": [
                    "indirect_endpoint"
                  ],
                  "ids": {
                    "pmid": "34567890",
                    "doi": "10.7759/cureus.17349"
                  },
                  "citations": [
                    {
                      "pmid": "34567890",
                      "doi": "10.7759/cureus.17349",
                      "title": "Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period."
                    }
                  ]
                },
                {
                  "study_key": "pmid:31234567",
                  "source": "pubmed",
                  "title": "Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography.",
                  "year": 2019,
                  "evidence_level": 6,
                  "study_type": "in_silico",
                  "population_class": "computational",
                  "endpoint_class": "mechanistic_only",
                  "effect_direction": "unknown",
                  "quality_flags": [],
                  "directness_flags": [
                    "indirect_endpoint"
                  ],
                  "ids": {
                    "pmid": "31234567",
                    "doi": "10.3390/s19122807"
                  },
                  "citations": [
                    {
                      "pmid": "31234567",
                      "doi": "10.3390/s19122807",
                      "title": "Assessment of the Spatial Distribution of Moisture Content in Granular Material Using Electrical Impedance Tomography."
                    }
                  ]
                },
                {
                  "study_key": "nct:NCT06658093",
                  "source": "clinicaltrials",
                  "title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
                  "year": 2028,
                  "evidence_level": 2,
                  "study_type": "registry_interventional",
                  "population_class": "human_registry",
                  "endpoint_class": "mechanistic_only",
                  "effect_direction": "unknown",
                  "quality_flags": [
                    "not_completed",
                    "no_registry_results"
                  ],
                  "directness_flags": [
                    "indirect_endpoint"
                  ],
                  "ids": {
                    "nct": "NCT06658093"
                  },
                  "citations": [
                    {
                      "nct": "NCT06658093",
                      "title": "RESTOR: PK/PD mTORi Inhibition in Older Adults"
                    }
                  ]
                },
                {
                  "study_key": "nct:NCT05836025",
                  "source": "clinicaltrials",
                  "title": "Effect of Rapamycin in Ovarian Aging",
                  "year": 2026,
                  "evidence_level": 2,
                  "study_type": "registry_interventional",
                  "population_class": "human_registry",
                  "endpoint_class": "mechanistic_only",
                  "effect_direction": "unknown",
                  "quality_flags": [
                    "not_completed",
                    "no_registry_results"
                  ],
                  "directness_flags": [
                    "indirect_endpoint"
                  ],
                  "ids": {
                    "nct": "NCT05836025"
                  },
                  "citations": [
                    {
                      "nct": "NCT05836025",
                      "title": "Effect of Rapamycin in Ovarian Aging"
                    }
                  ]
                }
              ],
              "optional_source_status": [
                {
                  "nct_id": "NCT06658093",
                  "status": "RECRUITING",
                  "has_results": false,
                  "completion_date": "2028-07",
                  "pmids": [],
                  "pubmed_match_mode": "none",
                  "openalex_ids": [],
                  "counts": {
                    "pmid_count": 0,
                    "openalex_count": 0
                  },
                  "flag": "no_mismatch_signal",
                  "warnings": []
                },
                {
                  "nct_id": "NCT05836025",
                  "status": "ACTIVE_NOT_RECRUITING",
                  "has_results": false,
                  "completion_date": "2026-09",
                  "pmids": [],
                  "pubmed_match_mode": "none",
                  "openalex_ids": [],
                  "counts": {
                    "pmid_count": 0,
                    "openalex_count": 0
                  },
                  "flag": "no_mismatch_signal",
                  "warnings": []
                }
              ]
            },
            "schema_path": "/Users/amt42/projects/hackathon-agent-core/schemas/evidence_report.schema.json"
          },
          "ids": [
            "sirolimus"
          ],
          "citations": [],
          "warnings": [
            "evidence_report.schema.json is missing; report emitted without schema validation."
          ],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "evidence_report_json.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260228T033857Z/lineages/tool-validate-run-20260228T033857Z/tools/evidence_render_report/manual-027/raw/evidence_report_json.json",
              "sha256": "fde70044e5ec276848b78c482dc6d5746cf756b8bbf51d57e554545e48530bdd",
              "size_bytes": 13502
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "evidence",
            "request_id": null,
            "retrieved_at": "2026-02-28T03:39:20.145366Z",
            "data_schema_version": "v2.1",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260228T033857Z",
              "run_id": "tool-validate-run-20260228T033857Z",
              "tool_use_id": "manual-027"
            }
          }
        }
      },
      "note": null,
      "latency_ms": 2.15,
      "endpoint": "internal",
      "enabled": true
    },
    {
      "tool": "dailymed_search_labels",
      "payload": {
        "drug_name": "sirolimus",
        "page": 1,
        "page_size": 10
      },
      "result": {
        "status": "skipped",
        "reason": "Tool disabled/not registered"
      },
      "note": null,
      "latency_ms": 0,
      "endpoint": "https://dailymed.nlm.nih.gov/dailymed/services/v2/spls.json",
      "enabled": false
    },
    {
      "tool": "dailymed_get_label_sections",
      "payload": {
        "setid": "2e9f8f43-a999-489f-a420-f5d0f170f71c"
      },
      "result": {
        "status": "skipped",
        "reason": "Tool disabled/not registered"
      },
      "note": "fallback setid",
      "latency_ms": 0,
      "endpoint": "https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/{setid}.json",
      "enabled": false
    },
    {
      "tool": "openfda_faers_aggregate",
      "payload": {
        "search": "patient.drug.medicinalproduct:SIROLIMUS",
        "count": "patient.reaction.reactionmeddrapt.exact",
        "limit": 5
      },
      "result": {
        "status": "error",
        "error": {
          "code": "VALIDATION_ERROR",
          "message": "'query' is required",
          "retryable": false,
          "details": {}
        }
      },
      "note": null,
      "latency_ms": 0.59,
      "endpoint": "https://api.fda.gov/drug/event.json",
      "enabled": true
    },
    {
      "tool": "hagr_drugage_refresh",
      "payload": {
        "dataset": "drugage"
      },
      "result": {
        "status": "skipped",
        "reason": "Tool disabled/not registered"
      },
      "note": null,
      "latency_ms": 0,
      "endpoint": "https://genomics.senescence.info/drugs/dataset.zip",
      "enabled": false
    },
    {
      "tool": "hagr_drugage_query",
      "payload": {
        "compound": "rapamycin",
        "limit": 10,
        "auto_refresh": true
      },
      "result": {
        "status": "skipped",
        "reason": "Tool disabled/not registered"
      },
      "note": null,
      "latency_ms": 0,
      "endpoint": "local_cache:hagr_drugage",
      "enabled": false
    },
    {
      "tool": "itp_fetch_survival_summary",
      "payload": {
        "url": "https://phenome.jax.org/itp/surv/MetRapa/C2011"
      },
      "result": {
        "status": "skipped",
        "reason": "Tool disabled/not registered"
      },
      "note": null,
      "latency_ms": 0,
      "endpoint": "https://phenome.jax.org/itp/surv/MetRapa/C2011",
      "enabled": false
    },
    {
      "tool": "chembl_search_molecules",
      "payload": {
        "query": "sirolimus",
        "limit": 5
      },
      "result": {
        "status": "skipped",
        "reason": "Tool disabled/not registered"
      },
      "note": null,
      "latency_ms": 0,
      "endpoint": "https://www.ebi.ac.uk/chembl/api/data/molecule/search.json",
      "enabled": false
    },
    {
      "tool": "chembl_get_molecule",
      "payload": {
        "chembl_id": "CHEMBL413"
      },
      "result": {
        "status": "skipped",
        "reason": "Tool disabled/not registered"
      },
      "note": "fallback ChEMBL",
      "latency_ms": 0,
      "endpoint": "https://www.ebi.ac.uk/chembl/api/data/molecule/{chembl_id}.json",
      "enabled": false
    },
    {
      "tool": "chebi_search_entities",
      "payload": {
        "query": "nicotinamide mononucleotide",
        "limit": 5
      },
      "result": {
        "status": "skipped",
        "reason": "Tool disabled/not registered"
      },
      "note": null,
      "latency_ms": 0,
      "endpoint": "https://www.ebi.ac.uk/chebi/backend/api/public/es_search/",
      "enabled": false
    },
    {
      "tool": "chebi_get_entity",
      "payload": {
        "chebi_id": "CHEBI:16708"
      },
      "result": {
        "status": "skipped",
        "reason": "Tool disabled/not registered"
      },
      "note": "fallback ChEBI",
      "latency_ms": 0,
      "endpoint": "https://www.ebi.ac.uk/chebi/backend/api/public/compound/{chebi_id}/",
      "enabled": false
    },
    {
      "tool": "openalex_search_works",
      "payload": {
        "query": "rapamycin aging",
        "per_page": 5
      },
      "result": {
        "status": "skipped",
        "reason": "Skipped by user request"
      },
      "note": "user requested skip",
      "latency_ms": 0,
      "endpoint": "https://api.openalex.org/works",
      "enabled": false
    },
    {
      "tool": "openalex_get_works",
      "payload": {
        "ids": [
          "https://openalex.org/W2741809807"
        ]
      },
      "result": {
        "status": "skipped",
        "reason": "Skipped by user request"
      },
      "note": "user requested skip",
      "latency_ms": 0,
      "endpoint": "https://api.openalex.org/works/{id}",
      "enabled": false
    }
  ]
}